<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en" article-type="research-article">
<?release-delay 0|0?>
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">WASJ</journal-id>
<journal-title-group>
<journal-title>World Academy of Sciences Journal</journal-title>
</journal-title-group>
<issn pub-type="ppub">2632-2900</issn>
<issn pub-type="epub">2632-2919</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">WASJ-7-3-00328</article-id>
<article-id pub-id-type="doi">10.3892/wasj.2025.328</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Inhibition of nasopharynx cancer cells by selected flavonoids <italic>in vitro</italic> and molecular docking analysis of BCL‑w anti‑apoptotic protein</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Daker</surname><given-names>Maelinda</given-names></name>
<xref rid="af1-WASJ-7-3-00328" ref-type="aff">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Gaurav</surname><given-names>Anand</given-names></name>
<xref rid="af2-WASJ-7-3-00328" ref-type="aff">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Akowuah</surname><given-names>Gabriel Akyirem</given-names></name>
<xref rid="af3-WASJ-7-3-00328" ref-type="aff">3</xref>
<xref rid="c1-WASJ-7-3-00328" ref-type="corresp"/>
</contrib>
</contrib-group>
<aff id="af1-WASJ-7-3-00328"><label>1</label>Molecular Pathology Unit, Cancer Research Centre, Institute for Medical Research, National Institutes of Health, Ministry of Health, Shah Alam, Selangor 40170, Malaysia</aff>
<aff id="af2-WASJ-7-3-00328"><label>2</label>Department of Pharmaceutical Sciences, School of Health Sciences, UPES, Dehradun, Uttarakhand 248007, India</aff>
<aff id="af3-WASJ-7-3-00328"><label>3</label>Monash University Malaysia, School of Pharmacy, Bandar Sunway, Subang Jaya, Selangor 47500, Malaysia</aff>
<author-notes>
<corresp id="c1-WASJ-7-3-00328"><italic>Correspondence to:</italic> Dr Gabriel Akyirem Akowuah, Monash University Malaysia, School of Pharmacy, Jalan Lagoon Selatan, Bandar Sunway, Subang Jaya, Selangor 47500, Malaysia <email>akow5@hotmail.com </email></corresp>
</author-notes>
<pub-date pub-type="collection">
<season>May-Jun</season>
<year>2025</year></pub-date>
<pub-date pub-type="epub">
<day>20</day>
<month>02</month>
<year>2025</year></pub-date>
<volume>7</volume>
<issue>3</issue>
<elocation-id>40</elocation-id>
<history>
<date date-type="received">
<day>10</day>
<month>07</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>04</day>
<month>02</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright: © 2025 Daker et al.</copyright-statement>
<copyright-year>2025</copyright-year>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.</license-p></license>
</permissions>
<abstract>
<p>Current treatments for nasopharyngeal carcinoma (NPC), a type of cancer that develops from the epithelium of the nasopharynx, are often associated with potential toxicities. Moreover, NPC continues to be a considerable cause of morbidity and mortality. The breakthrough of novel therapeutic strategies is crucial in order to obtain improved treatment results. B-cell lymphoma-w (BCL-w) is an anti-apoptotic member of the B-cell lymphoma-2 (BCL-2) family of proteins. BCL-w exhibits high conformational flexibility and could be exploited to develop inhibitors selective of BCL-w. The inhibition of BCL-w may benefit patients with cancer. Flavonoids exhibit diverse bioactivity, including anticancer activity. The present study investigated selected flavonoids, apigenin, kaempferol, luteolin, quercetin and their respective glycosides, for their inhibitory effects on NPC cells. Flavonoids were evaluated in a concentration- and time-dependent manner using a colorimetric assay, and the findings were then verified using a real-time, impedance-based cell analyser. Molecular docking analyses were conducted on the selected flavonoids against BCL-w as the target site. The aglycones (apigenin, kaempferol, luteolin and quercetin) were more potent than their respective <italic>O</italic>-glycosides, while the <italic>C</italic>-glycosides exhibited no activity on NPC cells. The molecular docking analyses of the selected flavonoids and their glycoside derivatives as ligands and the ligand binding site of BCL-w as the target site revealed varying degrees of binding affinity to the binding site. Cynaroside had the highest binding affinity among the flavonoids evaluated. Apigenin, luteolin, kaempferol and quercetin markedly inhibited NPC cell viability. Dietary flavones and flavonols may thus provide potency on NPC cells. The results from the molecular docking analyses may be further used in designing new derivatives with improved binding affinity with BCL-w.</p>
</abstract>
<kwd-group>
<kwd>flavonoids</kwd>
<kwd>flavones</kwd>
<kwd>flavonols</kwd>
<kwd>glycosides</kwd>
<kwd>molecular docking</kwd>
<kwd>nasopharyngeal carcinoma</kwd>
</kwd-group>
<funding-group>
<funding-statement><bold>Funding:</bold> The present study was financially supported by the Ministry of Health, Malaysia (NMRR-14-815-22074).</funding-statement>
</funding-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Among the continents, Asia recorded the highest incidence and mortality rates of nasopharyngeal carcinoma (NPC). GLOBOCAN 2022 (version 1.1) estimates that Malaysia is one of the Asian countries with the highest age-standardized rate (ASR) of NPC at 5.7 per 100,000 individuals (<xref rid="b1-WASJ-7-3-00328" ref-type="bibr">1</xref>). Moreover, according to ‘Cancer Tomorrow’ (<xref rid="b2-WASJ-7-3-00328" ref-type="bibr">2</xref>), the estimated number of new NPC cases in Malaysia will increase from 2,410 in 2022 to 3,660 in 2045. According to the National Cancer Registry, between 2012 and 2016, NPC was the fifth most common type of cancer among Malaysian males, with the incidence increasing rapidly after the age of 25 years and peaking at the age of 65 years (<xref rid="b3-WASJ-7-3-00328" ref-type="bibr">3</xref>). There were 4,597 cases of NPC in Malaysia between the years 2012 and 2016(<xref rid="b3-WASJ-7-3-00328" ref-type="bibr">3</xref>). Of note, ~69% of male and 65% of female patients with NPC in Malaysia present with late stages of the disease, at stages III and IV (<xref rid="b3-WASJ-7-3-00328" ref-type="bibr">3</xref>), leading to a 5-year relative survival rate of only ~46%, with a median survival time of 40.6 months (<xref rid="b4-WASJ-7-3-00328" ref-type="bibr">4</xref>). In Malaysia, NPC in childhood (ages 0-19 years) was the 7th and 9th most common type of cancer between the years 2007-2011 and 2012-2016, respectively (<xref rid="b5-WASJ-7-3-00328" ref-type="bibr">5</xref>).</p>
<p>NPC is the most common type of tumour that may develop in the nasopharynx (<xref rid="b6-WASJ-7-3-00328" ref-type="bibr">6</xref>,<xref rid="b7-WASJ-7-3-00328" ref-type="bibr">7</xref>). NPC, a type of cancer originating from the nasopharynx epithelium (<xref rid="b8-WASJ-7-3-00328" ref-type="bibr">8</xref>), is prevalent in Southern China, Southeast Asia, North Africa, and among the Eskimos of Alaska and Greenland (<xref rid="b9-WASJ-7-3-00328" ref-type="bibr">9</xref>). The Bidayuh, a native ethnic group of East Malaysia, has a predisposition for NPC (<xref rid="b10-WASJ-7-3-00328" ref-type="bibr">10</xref>). The ASR for Bidayuh was 24.6 per 100,000 males and 9.3 per 100,000 females (<xref rid="b10-WASJ-7-3-00328" ref-type="bibr">10</xref>). There are multiple risk factors involved in the development of NPC, including Epstein-Barr Virus (EBV) infection, genetic predisposition, diet, environmental exposure and tobacco smoking. The probable cancer-related risk factors contributing to the development of NPC among the Bidayuh population have been previously reviewed (<xref rid="b11-WASJ-7-3-00328" ref-type="bibr">11</xref>).</p>
<p>Flavonoids, low-molecular-weight polyphenolic compounds, are classified based on the carbon atom of ring C (closed pyran) to which ring B (benzene ring) is attached, the degree of unsaturation and oxidation of ring C (<xref rid="f1-WASJ-7-3-00328" ref-type="fig">Fig. 1</xref>) (<xref rid="b12-WASJ-7-3-00328" ref-type="bibr">12</xref>). Sub-classes of flavonoids include anthocyanins, chalcones, flavones, isoflavones and flavonols.</p>
<p>Patients undergoing locoregional therapy for advanced stages of NPC are treated with concurrent chemotherapy and radiotherapy (<xref rid="b13-WASJ-7-3-00328" ref-type="bibr">13</xref>,<xref rid="b14-WASJ-7-3-00328" ref-type="bibr">14</xref>). Cytotoxic chemotherapeutic drugs include cisplatin and 5-fluorouracil. However, the use of cisplatin is frequently associated with renal toxicity. Due to toxicities often associated with conventional cancer therapeutics, alternative, less toxic treatments are essential. There is a surge of interest in researching plant-derived flavonoids and their glycosides in human nutrition due to their health-related benefits for various chronic diseases, including cancer. Plant-derived flavonoids have the potential to be developed as an alternative therapy for the treatment of NPC with no side-effects. For example, quercetin was previously shown to reduce cisplatin toxicity in the LLC-PK<sub>1</sub> pig kidney-derived cell line (<xref rid="b15-WASJ-7-3-00328" ref-type="bibr">15</xref>). Another study demonstrated that in the kidneys of tumour-bearing rats, quercetin exhibited protective activity from toxic damage inflicted by cisplatin (<xref rid="b16-WASJ-7-3-00328" ref-type="bibr">16</xref>). Furthermore, another study demonstrated that <italic>in vivo</italic>, cynaroside (luteolin-7-O-glucoside) decreased cisplatin-induced nephrotoxicity in the kidneys of mice, whereas, <italic>in vitro</italic>, cynaroside reduced the cisplatin-induced death in human kidney proximal tubule HK-2 cells (<xref rid="b17-WASJ-7-3-00328" ref-type="bibr">17</xref>). Simultaneous reports of the inhibitory effects of flavonoids in their free forms and glycosides are uncommon. The present study aimed to determine the inhibitory effects of selected aglycones of flavones (apigenin and luteolin) and flavonols (kaempferol and quercetin) and their respective glycosides (apigetrin, vitexin, isovitexin, cynaroside, orientin, isoorientin, astragalin and isoquercitrin) (<xref rid="f2-WASJ-7-3-00328" ref-type="fig">Fig. 2</xref>) on C666-1 and HK1 cells, two cell lines often used as cell models for NPC. Finally, molecular docking was carried out against B-cell lymphoma-w (BCL-w) in an aim to better understand the mechanisms of action of flavones, flavonols and their glycosidic derivatives.</p>
<p>These flavones and flavonols were selected for the present study based on numerous literature reports of their inhibitory effects on various human cancer cell lines (<xref rid="b18-WASJ-7-3-00328 b19-WASJ-7-3-00328 b20-WASJ-7-3-00328 b21-WASJ-7-3-00328 b22-WASJ-7-3-00328 b23-WASJ-7-3-00328 b24-WASJ-7-3-00328" ref-type="bibr">18-24</xref>). Numerous literature reports exist on the therapeutic properties of flavonoids and their dietary applications (<xref rid="b25-WASJ-7-3-00328 b26-WASJ-7-3-00328 b27-WASJ-7-3-00328" ref-type="bibr">25-27</xref>). Medicinal properties of flavonoids are ascribed to their ability to prevent injuries caused by reactive oxygen and nitrogen species. Hydroxyl groups of flavonoids react with and convert radicals into stable forms (<xref rid="b28-WASJ-7-3-00328" ref-type="bibr">28</xref>). Flavonoids exhibit potent antioxidant properties by neutralizing free radicals and reducing oxidative stress, which plays a crucial role in cancer progression (<xref rid="b29-WASJ-7-3-00328" ref-type="bibr">29</xref>). Additionally, flavonoids modulate inflammatory responses, which may prove to be beneficial in the prevention and treatment of cancer (<xref rid="b30-WASJ-7-3-00328" ref-type="bibr">30</xref>). Previous studies have demonstrated that flavonoids induce the apoptosis (programmed cell death) of cancer cells, suggesting their potential use as anticancer agents (<xref rid="b29-WASJ-7-3-00328" ref-type="bibr">29</xref>,<xref rid="b31-WASJ-7-3-00328" ref-type="bibr">31</xref>). Moreover, flavonoids can target multiple molecular pathways involved in cancer cell survival and proliferation, demonstrating their effectiveness in inhibiting tumour growth (<xref rid="b31-WASJ-7-3-00328" ref-type="bibr">31</xref>). Furthermore, apigenin (<xref rid="b32-WASJ-7-3-00328" ref-type="bibr">32</xref>), luteolin (<xref rid="b33-WASJ-7-3-00328" ref-type="bibr">33</xref>,<xref rid="b34-WASJ-7-3-00328" ref-type="bibr">34</xref>) and kaempferol (<xref rid="b35-WASJ-7-3-00328" ref-type="bibr">35</xref>) have been found to inhibit EBV reactivation, a key factor in NPC, as NPC is strongly associated with EBV (<xref rid="b36-WASJ-7-3-00328" ref-type="bibr">36</xref>).</p>
</sec>
<sec sec-type="Materials|methods">
<title>Materials and methods</title>
<sec>
<title/>
<sec>
<title>Chemicals</title>
<p>Apigenin, apigetrin, astragalin, cynaroside, isoorientin, isoquercitrin, isovitexin, kaempferol, luteolin, orientin, quercetin and vitexin were purchased from Merck KGaA. The purity of all the flavonoids was ≥98%, determined by high-performance liquid chromatography (data not shown). Cisplatin was obtained from Cayman Chemical Co.</p>
</sec>
<sec>
<title>In vitro evaluation of NPC cell viability inhibition. Cells and cell culture</title>
<p>HK1(<xref rid="b37-WASJ-7-3-00328" ref-type="bibr">37</xref>), an NPC cell line, was maintained in Roswell Park Memorial Institute (RPMI)-1640 (Gibco; Thermo Fisher Scientific, Inc.) medium supplemented with 10% heat-inactivated foetal calf serum (FCS; Gibco; Thermo Fisher Scientific, Inc.), 10 U/ml penicillin (Gibco; Thermo Fisher Scientific, Inc.) and 10 µg/ml streptomycin (Gibco; Thermo Fisher Scientific, Inc.) in a 5% carbon dioxide (CO<sub>2</sub>) humidified atmosphere at 37˚C. The C666-1 cells (<xref rid="b38-WASJ-7-3-00328" ref-type="bibr">38</xref>), another NPC cell line, was maintained in a similar manner, apart from the addition of 1X GlutaMAX-I Supplement (Gibco; Thermo Fisher Scientific, Inc.). HaCaT (<xref rid="b39-WASJ-7-3-00328" ref-type="bibr">39</xref>) cells, an immortalised human skin keratinocyte cell line, was maintained in Dulbecco's Modified Eagle Medium (DMEM) (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% FCS. The HaCaT cell line (cell cat. no. 300493) was procured from CLS Cell Lines Service GmbH. The HaCaT cell line, as well as the immortalised nasopharyngeal epithelial cell lines, NP460hTERT (<xref rid="b40-WASJ-7-3-00328" ref-type="bibr">40</xref>) and NP69SV40T (<xref rid="b41-WASJ-7-3-00328" ref-type="bibr">41</xref>), represented normal cells. NP69SV40T was maintained in 1X keratinocyte serum-free medium (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 25 µg/ml bovine pituitary extract and 0.16 ng/ml recombinant epidermal growth factor. The NP460hTERT cells were maintained at a 1:1 ratio of 1X defined keratinocyte serum-free medium (Gibco; Thermo Fisher Scientific, Inc.) with the addition of growth supplement: EpiLife Medium (Gibco; Thermo Fisher Scientific, Inc.) with EpiLife Defined Growth Supplement (Cascade Biologics, Life Technologies; Thermo Fisher Scientific, Inc.). DNA fingerprinting for HK1, C666-1, NP69SV40T and NP460hTERT cells was performed using the AmpFISTRIdentifiler<sup>®</sup> polymerase chain reaction amplification kit (Applied Biosystems; Thermo Fisher Scientific, Inc.). The routine detection of the mycoplasma contamination was carried out using the <italic>e</italic>-Myco™ Mycoplasma Polymerase chain reaction (PCR) Detection Kit (iNtRON Biotechnology, Inc,), according to the protocol of the manufacturer. Only mycoplasma-free cells were used throughout the study.</p>
<p><italic>Evaluation of cell viability inhibition using MTS assay.</italic> A total of 5,000-30,000 C666-1, HK1, NP460hTERT, NP69SV40T and HaCaT cells/100 µl medium/well were seeded in 96-well microtiter plates and returned into the incubator at 37˚C in a 5% CO<sub>2</sub> atmosphere for 1 day. After 1 day, the culture medium was aspirated and replaced with 100 µl freshly prepared culture medium containing 0-300 µM flavonoids dissolved in dimethyl sulfoxide (DMSO) (MilliporeSigma). The solvent control group was cells in 0.5% DMSO. The microtiter plates were returned to the incubator for 1-3 days. Using the CellTiter 96<sup>®</sup> AQ<sub>ueous</sub> One Solution Cell Proliferation (MTS) assay (Promega Corporation) as previously described (<xref rid="b42-WASJ-7-3-00328" ref-type="bibr">42</xref>), the percentage MTS signal was obtained after 1-3 days to determine whether flavonoids could inhibit the cells. Briefly, 20 µl MTS reagent were added to each well and the microtiter plates were returned to the incubator for 1-4 h, according to the optimal incubation time for MTS reagent. The absorbance at 490 nm and non-specific absorbance at 630 nm was measured using an EnVision multilabel plate reader (PerkinElmer, Inc.). Wells with medium but without cells served as the blank control. The percentage of MTS signal was calculated and compared to that of the solvent control group. Dose-response curves for 1-3 days of flavonoid exposure were plotted. IC<sub>50</sub> values, specifically the effective concentration that inhibited 50% MTS signal relative to the solvent control group, were obtained by using non-linear regression (curve fit) on GraphPad Prism version 6.07 for Windows (Dotmatics). At least three independent experiments were performed, and the average IC<sub>50</sub> value was reported. Statistical analysis, as for example, using a t-test or ANOVA, is not typically performed for reports of IC<sub>50</sub> values. Rather, the IC<sub>50</sub> values of the flavonoids were compared to cisplatin, a conventional chemotherapeutic drug for NPC, and used herein as the positive control. Cisplatin (0-300 µM) was assayed for 1-3 days. Additionally, calculating the selectivity index of the flavonoids and standard chemotherapeutic drugs is also useful. The selectivity index (SI) was calculated as the ratio of IC<sub>50</sub> values in normal cells to cancer cells (<xref rid="b43-WASJ-7-3-00328" ref-type="bibr">43</xref>).</p>
<p><italic>xCELLigence cell inhibition assay</italic>. The C666-1, HK1, NP460hTERT, NP69SV40T and HaCaT cells were seeded at a density of 5,000-3,0000 cells/100 µl medium/well into E-Plate 16 (ACEA Biosciences, Inc.) for 1 day. The culture medium was then aspirated and replaced with 100 µl freshly prepared medium containing apigenin, kaempferol, or luteolin, or their respective glucoside to a final concentration of 25, 50, or 100 µM. Cells in 0.5% DMSO were the solvent control group. The growth pattern of the cells was monitored dynamically on the impedance-based real-time cell analyser xCELLigence RTCA DP (ACEA Biosciences, Inc.) for a further 76 h at 37˚C in a 5% CO<sub>2</sub> atmosphere to validate the effect of flavonoids on cells. Throughout the 76-h period, the culture medium was neither aspirated nor replaced. The data analysis software used was RTCA version 2.0 (ACEA Biosciences, Inc.). The cell index was normalised to the time immediately point prior to the addition of the flavonoids. At least three independent experiments were performed.</p>
</sec>
<sec>
<title>Molecular docking analyses. Protein preparation</title>
<p>The three-dimensional (3D) structure of BCL-w (PDB ID: 2Y6W) (<xref rid="b44-WASJ-7-3-00328" ref-type="bibr">44</xref>) was selected and downloaded from Protein Data Bank (PDB) (<xref rid="b45-WASJ-7-3-00328" ref-type="bibr">45</xref>). Biovia Discovery Studio (DS) (Biovia) (<xref rid="b46-WASJ-7-3-00328" ref-type="bibr">46</xref>) and AutoDock Tools 1.5.6 (ADT) (<xref rid="b47-WASJ-7-3-00328" ref-type="bibr">47</xref>) were used to prepare the protein for docking. The protein structure was imported to AutoDock to remove the water molecules and add the polar hydrogen atoms and Gasteiger charges. Finally, the protein structures were saved in pdbqt format.</p>
<p><italic>Ligand preparation.</italic> ChemSketch Software version 2019 (Advanced Chemistry Development, Inc.) was used to draw the 2D structures of the selected flavones, flavonols and their glycosidic derivatives. Biovia DS was used to convert the 2D structures of the compound into their respective 3D structures, and the geometry was optimised using a DREIDING-like forcefield. The 3D structures of the ligands were imported into AutoDock, where ADT was used to prepare the ligands for docking by adding charges, setting the rotatable bonds, and allowing all the torsions to rotate for the ligands. All the ligands were then saved in pdbqt format.</p>
<p><italic>Identification of the binding site.</italic> The binding site of protein structure was identified based on the residues previously reported in the literature (<xref rid="b48-WASJ-7-3-00328" ref-type="bibr">48</xref>). ADT was used to determine the Grid Box that covers the entire identified binding site of the protein. The coordinates and sizes of the Grid Box were saved in the input parameter file.</p>
<p><italic>Molecular docking.</italic> After preparing the protein structure, ligands and the input parameter file, molecular docking was performed using AutoDock Vina 1.1.2. (<xref rid="b49-WASJ-7-3-00328" ref-type="bibr">49</xref>,<xref rid="b50-WASJ-7-3-00328" ref-type="bibr">50</xref>). The prepared ligands were docked into the active sites of the prepared target protein. All the docking parameters have remained as default settings. The binding affinities of the ligands were recorded and compared. The binding poses of the ligands and the mode of interactions of the protein-ligand complex were studied using Biovia DS.</p>
</sec>
</sec>
</sec>
<sec sec-type="Results">
<title>Results</title>
<sec>
<title/>
<sec>
<title>In vitro evaluation of NPC cell viability inhibition</title>
<p>A preliminary screening involving four pure compounds, apigenin, kaempferol, luteolin and quercetin, and their respective glucosides was performed using MTS assay. Effective concentrations required to inhibit 50% MTS signal were attained from concentration-response curves. As a solvent control group, DMSO did not influence the percentage of MTS signal. Generally, apigenin, kaempferol, luteolin and quercetin exerted time- and concentration-dependent inhibitory effects (<xref rid="f3-WASJ-7-3-00328" ref-type="fig">Fig. 3A-D</xref> and Table SI). Apigenin, kaempferol, luteolin, and quercetin were more effective against the cell lines tested; in most cases, IC<sub>50</sub> values of apigenin, kaempferol, luteolin and quercetin were lower than their glucoside equivalents. On the whole, IC<sub>50</sub> values of the glucoside equivalents were unreachable (<xref rid="f3-WASJ-7-3-00328" ref-type="fig">Fig. 3A-D</xref> and Table SI). However, even at the highest concentration tested, vitexin, isovitexin, cynaroside, orientin, isoorientin and astragalin did not markedly inhibit the cell lines tested (Table SI). Cisplatin, a standard chemotherapeutic drug used for the treatment of NPC, killed immortalised nasopharyngeal epithelial cells and immortalised human skin keratinocytes, in addition to NPC cells (<xref rid="f3-WASJ-7-3-00328" ref-type="fig">Fig. 3E</xref> and Table SI). Due to the toxicities frequently associated with cisplatin, alternative, less toxic treatments are essential. The SI is a calculation used to evaluate the toxicity of compounds against normal cells (<xref rid="b51-WASJ-7-3-00328" ref-type="bibr">51</xref>). A higher SI value means that cancer cells could be killed more than normal cells; thus, SI can predict the therapeutic potential (<xref rid="b51-WASJ-7-3-00328" ref-type="bibr">51</xref>). An SI&gt;2 is favourable for a compound to be an effective anticancer agent (<xref rid="b43-WASJ-7-3-00328" ref-type="bibr">43</xref>). Thus, herein, where the IC<sub>50</sub> could be attained, the SI values of cisplatin, apigenin, kaempferol, luteolin, quercetin and their glucoside equivalents on NPC cells against normal cells were determined (<xref rid="tI-WASJ-7-3-00328" ref-type="table">Table I</xref>). Apigetrin was the most selective flavonoid tested between normal and NPC cells, with SI values ranging between 2.490 and 3.073 (<xref rid="tI-WASJ-7-3-00328" ref-type="table">Table I</xref>).</p>
<p>In order to verify the results of MTS assay, growth kinetics were monitored dynamically through the xCELLigence system, a real-time, impedance-based cell analyser used to quantify adherent cell proliferation, cell viability, and cytotoxicity non-invasively. The cell index, a dimensionless parameter, increased in correspondence to impedance amplification within the electrical circuit caused by more cells deposited on the bottom of the well. The cell index represented growth or proliferation over time. The normalised cell index generated by NPC cells and nasopharyngeal epithelial cells in kaempferol was markedly lower than that of the control cells; 100 µM kaempferol led to a near-static normalised cell index (<xref rid="f4-WASJ-7-3-00328" ref-type="fig">Fig. 4A</xref>). Apigenin essentially yielded similar results in NPC cells and nasopharyngeal epithelial cells, evident from the rapid decline of the normalised cell index compared to the control cells (<xref rid="f4-WASJ-7-3-00328" ref-type="fig">Fig. 4B</xref>). Luteolin produced a similar effect on human skin keratinocytes (<xref rid="f4-WASJ-7-3-00328" ref-type="fig">Fig. 4C</xref>). Cells exposed to astragalin (<xref rid="f3-WASJ-7-3-00328" ref-type="fig">Figs. 3A</xref> and <xref rid="f4-WASJ-7-3-00328" ref-type="fig">4A</xref>) or cynaroside (<xref rid="f3-WASJ-7-3-00328" ref-type="fig">Figs. 3C</xref> and <xref rid="f4-WASJ-7-3-00328" ref-type="fig">4C</xref>) were not inhibited. The normalised cell index in astragalin or cynaroside was comparable to the control cells (<xref rid="f4-WASJ-7-3-00328" ref-type="fig">Fig. 4A</xref> and <xref rid="f4-WASJ-7-3-00328" ref-type="fig">C</xref>). Finally, dynamic monitoring demonstrated that apigetrin inhibited NPC cells and nasopharyngeal epithelial cells to a certain extent (<xref rid="f3-WASJ-7-3-00328" ref-type="fig">Figs. 3B</xref> and <xref rid="f4-WASJ-7-3-00328" ref-type="fig">4B</xref>). Thus, the outcomes of the xCELLigence system were in agreement with those of the MTS assay.</p>
</sec>
<sec>
<title>Docking analyses</title>
<p>C666-1 and HK1, two cell lines often used as cell models for NPC, express all the anti-apoptotic genes, including <italic>BCL-w</italic>, apart from for <italic>BFL-1</italic> in C666-1(<xref rid="b52-WASJ-7-3-00328" ref-type="bibr">52</xref>). In the present study, in order to better understand the mechanisms of action of the selected flavones, flavonols and their glycosidic derivatives, molecular docking analyses were carried out against BCL-w as the target site. Cynaroside possessed the highest binding affinity among all flavones, flavonols and their glycoside derivatives (<xref rid="tII-WASJ-7-3-00328" ref-type="table">Table II</xref>). Cynaroside was followed by apigetrin, followed by both isoorientin and isovitexin. Apigenin and kaempferol had the lowest affinities for BCL-w. In general, the <italic>O</italic>-glycosides demonstrated the highest binding affinity, followed by the <italic>C</italic>-glycosides, and the aglycones exhibited the lowest affinities for BCL-w. The evaluation of the binding modes revealed that the binding modes of cynaroside and apigetrin were relatively similar, and they are bound to the ligand binding pocket (<xref rid="f5-WASJ-7-3-00328" ref-type="fig">Figs. 5</xref> and <xref rid="f6-WASJ-7-3-00328" ref-type="fig">6</xref>). On the other hand, isoorientin and isovitexin (<xref rid="f7-WASJ-7-3-00328" ref-type="fig">Figs. 7</xref> and <xref rid="f8-WASJ-7-3-00328" ref-type="fig">8</xref>) exhibited relatively different binding modes from cynaroside and apigetrin. Isoorientin and isovitexin bound to a pocket adjacent to the pocket where cynaroside and apigetrin were bound. The binding interactions demonstrated by isoorientin and isovitexin also differed from those of cynaroside and apigetrin. Cynaroside formed hydrogen bonds with glycine 90 and phenylalanine 102, while it formed hydrophobic interactions via its chromene ring with arginine 56 and leucine 86. Apigetrin formed a hydrogen bond with glycine 90 and hydrophobic interactions via its chromene ring with arginine 56 and leucine 86 and the phenyl ring with phenylalanine 102. The binding interactions of isoorientin and isovitexin with the BCL-w binding site included hydrogen bonds with leucine 86 and arginine 95, and hydrophobic interactions via its chromene.</p>
</sec>
</sec>
</sec>
<sec sec-type="Discussion">
<title>Discussion</title>
<p>Previous studies have demonstrated the inhibitory effects of flavonoids on various human cancer cell lines. Flavones and flavonols have been reported to be the most bioactive flavonoids against gastric and pancreatic cancer (<xref rid="b53-WASJ-7-3-00328" ref-type="bibr">53</xref>,<xref rid="b54-WASJ-7-3-00328" ref-type="bibr">54</xref>). Among other chemicals, kaempferol, apigenin, luteolin and quercetin have been shown to inhibit OVCAR-3 ovarian cancer cell proliferation (<xref rid="b55-WASJ-7-3-00328" ref-type="bibr">55</xref>). In another study, in human leukaemia Jurkat T-cells, the order of potency at 24 h post-treatment was apigenin &gt; quercetin &gt; kaempferol &gt; myricetin (<xref rid="b56-WASJ-7-3-00328" ref-type="bibr">56</xref>). Moreover, among various flavonoids, apigenin, genistein and luteolin were shown to significantly reduce human colorectal cancer HCT-116 cell growth (<xref rid="b57-WASJ-7-3-00328" ref-type="bibr">57</xref>). In addition, amongst other flavones and isoflavones, apigenin was the most effective compound for arresting cell growth (<xref rid="b57-WASJ-7-3-00328" ref-type="bibr">57</xref>). It was previously demonstrated that apigenin 7-glucoside inhibited human promyelocytic leukaemia HL-60 cell proliferation (<xref rid="b58-WASJ-7-3-00328" ref-type="bibr">58</xref>). Luteolin was shown to inhibit NPC CNE2(<xref rid="b59-WASJ-7-3-00328" ref-type="bibr">59</xref>) and NPC HK1, C17, C666-1 and NPC 43 cell growth (<xref rid="b42-WASJ-7-3-00328" ref-type="bibr">42</xref>). Treatment with 100 µM quercetin for 3 days was also shown to inhibit NPC C666-1 and HK1 cells (<xref rid="b19-WASJ-7-3-00328" ref-type="bibr">19</xref>). Similarly, was found to quercetin abrogate the proliferation and induce the death of NPC 5-8F and C666-1 cells (<xref rid="b22-WASJ-7-3-00328" ref-type="bibr">22</xref>).</p>
<p>Flavones and flavonols are predominant classes of flavonoids. The structure of flavones has a double bond between positions 2 and 3 and a ketone in position 4 of the C ring (<xref rid="f2-WASJ-7-3-00328" ref-type="fig">Fig. 2</xref>). Flavonols, also known as 3-hydroxyflavone, are structurally similar to flavones, apart from for the addition of a hydroxyl group in position 3 of ring C (<xref rid="f2-WASJ-7-3-00328" ref-type="fig">Fig. 2</xref>). Flavones and flavonols occur in nature in a free state (aglycones) and as <italic>O</italic>- or <italic>C</italic>-glycosides, where the sugar moiety is linked to the hydroxy group of the aglycone (<italic>O</italic>-glycoside) or directly to the carbon atom of the aglycone (<italic>C</italic>-glycoside). Apigenin, luteolin, kaempferol and quercetin were effective against the cell lines tested in the present study. Notably, the inhibitory activity of apigenin and luteolin was higher than that of kaempferol and quercetin. The number of hydroxy groups on ring B of flavone and flavonol aglycones was observed to influence the inhibitory effect, as apigenin exhibited better activity than luteolin, whilst kaempferol exhibited better activity than quercetin. Apigenin and kaempferol have one hydroxy group on ring B, while luteolin and quercetin have two hydroxyl groups on ring B (<xref rid="f2-WASJ-7-3-00328" ref-type="fig">Fig. 2</xref>). Thus, increasing the solubility of molecules by introducing hydroxy functions may not be suitable for the <italic>in vitro</italic> assays described herein. This was further confirmed by comparing aglycones with their respective glycosides. Glycosides are bioactive aglycone and glucosyl group conjugations. Aglycones (apigenin, kaempferol, luteolin and quercetin) were more effective against the cell lines tested as compared to the respective <italic>O</italic>-glycosides and <italic>C</italic>-glycosides (<xref rid="f3-WASJ-7-3-00328" ref-type="fig">Fig. 3</xref> and Table SI). <italic>In vitro</italic>, the inhibitory effect of <italic>O</italic>-glycosides was relatively higher than their corresponding <italic>C</italic>-glycosides. Even at the highest concentration tested, <italic>C</italic>-glycosides (vitexin, isovitexin, orientin, and isoorientin) had no marked inhibitory effect on the cell lines assessed (Table SI). Such a report on NPC cells has not been made available to date, at least to the best of our knowledge. However, one limitation of the present study is the absence of statistical analysis.</p>
<p>The efficacy of flavonoids and their glycoside derivatives in inhibiting NPC cells has been well-documented (<xref rid="b29-WASJ-7-3-00328" ref-type="bibr">29</xref>). It has been shown that these compounds exhibit significant anticancer effects, such as the induction of apoptosis and induction of numerous signalling pathways, thus inhibiting NPC cell growth and proliferation (<xref rid="b60-WASJ-7-3-00328" ref-type="bibr">60</xref>). Flavonoids are known to neutralize free radicals, reduce oxidative stress and modulate inflammatory responses, which are essential in preventing cancer progression and causing cell cycle arrest (<xref rid="b61-WASJ-7-3-00328" ref-type="bibr">61</xref>). It has been shown that the use of 100 µM quercetin arrested HK1 NPC cells at the G2/M phase (<xref rid="b19-WASJ-7-3-00328" ref-type="bibr">19</xref>). Moreover, quercetin was found to decrease the expression of fatty acid synthase (FASN) and Ki67(<xref rid="b19-WASJ-7-3-00328" ref-type="bibr">19</xref>). The expression of FASN is elevated in highly proliferating cancer cells to accommodate intensified fatty acid synthesis (<xref rid="b62-WASJ-7-3-00328" ref-type="bibr">62</xref>), while Ki67 antigen is a cell proliferation marker. Luteolin is particularly effective in triggering ferroptosis and inhibiting the proliferation of NPC cells. It interferes with pathways involved in cancer cell survival and growth (<xref rid="b63-WASJ-7-3-00328" ref-type="bibr">63</xref>). Additionally, quercetin or luteolin, combined with cisplatin, produced synergistic effects against NPC cells (<xref rid="b19-WASJ-7-3-00328" ref-type="bibr">19</xref>,<xref rid="b42-WASJ-7-3-00328" ref-type="bibr">42</xref>). Morusin, a flavonoid obtained from the <italic>Morus</italic> plant, targets various molecular targets and signalling pathways, hindering the growth of NPC (<xref rid="b64-WASJ-7-3-00328" ref-type="bibr">64</xref>). Glycoside derivatives of flavonoids have an advantage over aglycones due to their enhanced bioavailability and targeted actions, which improve their anticancer effects. Glycoside derivatives improve the bioavailability of flavonoids, leading to increased apoptotic protein expression and ultimately causing cell death in cancer cells (<xref rid="b65-WASJ-7-3-00328" ref-type="bibr">65</xref>). Moreover, glycoside derivatives have demonstrated targeted effects on various cancer cells, triggering necroptosis, apoptosis, and cell cycle arrest (<xref rid="b65-WASJ-7-3-00328" ref-type="bibr">65</xref>).</p>
<p>BCL-w is an anti-apoptotic member of the B-cell lymphoma-2 (BCL-2) family of proteins that integrate signals that prompt cell survival or apoptosis (<xref rid="b66-WASJ-7-3-00328" ref-type="bibr">66</xref>). Several signalling pathways control the BCL-w level. BCL-w levels have been found to be elevated in various types of cancer. Increased levels of BCL-w may be ascribed to the abnormal activation of signalling cascades involved in regulating BCL-w expression (<xref rid="b67-WASJ-7-3-00328" ref-type="bibr">67</xref>). Increased levels of BCL-w, together with oncogene activation, contribute to cancer development and progression. The inhibition of BCL-w may benefit patients with cancer. To date, to the best of our knowledge, no known agents selectively target BCL-w (<xref rid="b67-WASJ-7-3-00328" ref-type="bibr">67</xref>). BCL-w exhibits a high conformational flexibility (<xref rid="b67-WASJ-7-3-00328" ref-type="bibr">67</xref>). Therefore, it would be advantageous to elucidate how this conformational flexibility could be used to develop inhibitors selective of BCL-w (<xref rid="b67-WASJ-7-3-00328" ref-type="bibr">67</xref>). Drugs and natural compounds that affect BCL-w levels, including the downregulation of BCL-w protein expression levels by cisplatin in the JHU-029 head and neck squamous cell carcinoma cell line, have been reviewed comprehensively (<xref rid="b67-WASJ-7-3-00328" ref-type="bibr">67</xref>). Quercetin has been shown to decrease <italic>BCL-w</italic> mRNA expression in N2a mouse neuroblastoma cell line (<xref rid="b68-WASJ-7-3-00328" ref-type="bibr">68</xref>). The docking scores of matrine, used to treat diverse cancers, including NPC, and matrine-derivatives, have been reported (<xref rid="b48-WASJ-7-3-00328" ref-type="bibr">48</xref>). However, to the best of our knowledge, no study available to date has described the potential of flavonoids to be developed as inhibitors selective for BCL-w in NPC.</p>
<p>Flavonoids induce the apoptosis of cancer cells by binding to BCL-w and disrupting its anti-apoptotic function (<xref rid="b69-WASJ-7-3-00328" ref-type="bibr">69</xref>). A comparison of the binding sites of different flavonoids with BCL-w reveals both similarities and differences in their molecular interactions and structural features (<xref rid="b70-WASJ-7-3-00328" ref-type="bibr">70</xref>). Variations in binding affinities to BCL-w among different flavonoids can affect their potency and efficacy in inducing apoptosis. The specific amino acids involved in binding interactions may differ among flavonoids, leading to variations in their biological activity (<xref rid="b70-WASJ-7-3-00328" ref-type="bibr">70</xref>). Structural features of flavonoids, such as the presence of hydroxyl groups and glycosylation, can influence their binding to BCL-w and overall biological activity. The hydroxyl groups of flavonoids form hydrogen bonds with specific amino acids in the binding site of BCL-w, enabling interaction and potential inhibition of BCL-w activity (<xref rid="b71-WASJ-7-3-00328" ref-type="bibr">71</xref>). However, differences in the orientation and positioning of these groups among different flavonoids can result in varying degrees of binding affinity and biological activity. Flavonoids with higher binding affinity and optimal structural features are more effective at inducing apoptosis in cancer cells by disrupting BCL-w function (<xref rid="b67-WASJ-7-3-00328" ref-type="bibr">67</xref>). For example, a flavonoid with additional hydroxyl groups may exhibit stronger interactions with key amino acids in the binding site, leading to increased biological activity by enhancing the inhibition of BCL-w. Conversely, another flavonoid with a different orientation of hydroxyl groups may have reduced binding affinity and lower biological activity. Therefore, understanding these structural differences in binding sites and their impact on biological activity is essential for the rational design of flavonoid-based compounds with enhanced BCL-w inhibitory effects (<xref rid="b70-WASJ-7-3-00328" ref-type="bibr">70</xref>).</p>
<p>In the present study, cynaroside exhibited the highest binding affinity for BCL-w, followed by apigetrin, while isoorientin and isovitexin exhibited moderate affinities. Apigenin and kaempferol recorded the lowest affinities for BCL-w. The structural variances between the compounds, such as the presence and position of the sugar groups, markedly influence their binding affinities and, consequently, their biological activities (<xref rid="b72-WASJ-7-3-00328" ref-type="bibr">72</xref>). Overall, the <italic>O</italic>-glycosides demonstrated the highest binding affinities, followed by the <italic>C</italic>-glycoside glycosides, with aglycones having the least affinity for BCL-w. The presence of glycoside moieties enhances the binding affinity compared to the aglycones, which lack the sugar groups. Additionally, the glycoside moiety enhances solubility and bioavailability, which is crucial for the interaction with BCL-w (<xref rid="b73-WASJ-7-3-00328" ref-type="bibr">73</xref>). The higher binding activity of the <italic>O</italic>-glycosides compared to the <italic>C</italic>-glycosides may be attributed to their flexibility. The <italic>O</italic>-glycoside bond provides more flexibility compared to the <italic>C</italic>-glycoside bond, facilitating better fitting and binding to the protein's active site (<xref rid="b65-WASJ-7-3-00328" ref-type="bibr">65</xref>). <italic>O</italic>-glycosides are relatively stable in physiological conditions, leading to sustained interactions with target proteins (<xref rid="b74-WASJ-7-3-00328" ref-type="bibr">74</xref>). The higher the binding activity to BCL-w, the more effective the compound will likely be in disrupting its anti-apoptotic function and inducing apoptosis in cancer cells.</p>
<p>In conclusion, in the present study, 12 flavonoids were screened <italic>in vitro</italic> for cell inhibition. The present study demonstrated that apigenin, kaempferol, luteolin and quercetin consistently inhibited NPC cells, nasopharyngeal epithelial cells, or skin keratinocytes. Inhibition by apigenin, kaempferol, luteolin and quercetin was more notable than their glucoside equivalents. <italic>O</italic>-glycosides inhibited cells to a lesser extent, whilst <italic>C</italic>-glycosides, namely vitexin, isovitexin, orientin and isoorientin, did not exert any inhibitory effect. The molecular docking analyses highlighted the relative binding affinities of the selected flavonoids to BCL-w, indicating that glycosides, particularly <italic>O</italic>-glycosides, such as cynaroside, have superior binding capabilities compared to aglycones like apigenin and kaempferol. This suggests that structural modifications, such as glycosylation, enhance the anticancer efficacy of flavonoids. The molecular docking analyses also revealed the importance of the chromene rings of flavones, flavonols and their glycosidic derivatives in forming critical hydrophobic interactions with the binding site residues of BCL-w. These findings can be further used in designing new derivatives with better binding affinity with BCL-w protein.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>The authors would like to thank the Director General of Health Malaysia for permission to publish this article. HK1, NP69SV40T and NP460hTERT cells were from the late Professor G.S.W. Tsao (The University of Hong Kong), whilst C666-1 cells were from Professor K.W. Lo (The Chinese University of Hong Kong).</p>
</ack>
<sec sec-type="data-availability">
<title>Availability of data and materials</title>
<p>The data generated in the present study may be requested from the corresponding author.</p>
</sec>
<sec>
<title>Authors' contributions</title>
<p>MD acquired and analysed the <italic>in vitro</italic> data and was a major contributor to the writing of the manuscript. AG performed the molecular docking analyses and was involved in drafting the manuscript. GAA contributed to the conception and design of the study, as well as the interpretation of the chemistry data and revision of the manuscript. MD and AG confirm the authenticity of all raw data. All authors have read and approved the final manuscript.</p>
</sec>
<sec>
<title>Ethics approval and consent to participate</title>
<p>The Medical Research and Ethics Committee (MREC), Ministry of Health Malaysia, has determined that the presaent study does not require MREC approval as the research does not involve human subjects.</p>
</sec>
<sec>
<title>Patient consent for publication</title>
<p>Not applicable.</p>
</sec>
<sec sec-type="COI-statement">
<title>Competing interests</title>
<p>The authors declare that they have no competing interests.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="b1-WASJ-7-3-00328"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Ervik</surname><given-names>M</given-names></name><name><surname>Lam</surname><given-names>F</given-names></name><name><surname>Laversanne</surname><given-names>M</given-names></name><name><surname>Colombet</surname><given-names>M</given-names></name><name><surname>Mery</surname><given-names>L</given-names></name><name><surname>Piñeros</surname><given-names>M</given-names></name><name><surname>Znaor</surname><given-names>A</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name></person-group><comment>Global Cancer Observatory: Cancer Today (version 1.1). International Agency for Research on Cancer, Lyon, 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://gco.iarc.fr/today">https://gco.iarc.fr/today</ext-link>. Accessde November 25, 2024.</comment></element-citation></ref>
<ref id="b2-WASJ-7-3-00328"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Ervik</surname><given-names>M</given-names></name><name><surname>Lam</surname><given-names>F</given-names></name><name><surname>Laversanne</surname><given-names>M</given-names></name><name><surname>Colombet</surname><given-names>M</given-names></name><name><surname>Mery</surname><given-names>L</given-names></name><name><surname>Piñeros</surname><given-names>M</given-names></name><name><surname>Znaor</surname><given-names>A</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name></person-group><comment>Global Cancer Observatory: Cancer Tomorrow (version 1.1). International Agency for Research on Cancer, Lyon, 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://gco.iarc.fr/tomorrow">https://gco.iarc.fr/tomorrow</ext-link>. Accessed November 25, 2024.</comment></element-citation></ref>
<ref id="b3-WASJ-7-3-00328"><label>3</label><element-citation publication-type="journal"><comment>Malaysia National Cancer Registry Report 2012-2016. National Cancer Registry Department, National Cancer Institute, Ministry of Health, Malaysia, 2019.</comment></element-citation></ref>
<ref id="b4-WASJ-7-3-00328"><label>4</label><element-citation publication-type="journal"><comment>Malaysian Study on Cancer Survival (MySCan). National Cancer Registry, National Cancer Institute, Ministry of Health Malaysia, Malaysia, 2018.</comment></element-citation></ref>
<ref id="b5-WASJ-7-3-00328"><label>5</label><element-citation publication-type="journal"><comment>Incidence of Childhood Cancer in Malaysia 2007-2016. National Cancer Registry Department, Institut Kanser Negara, Ministry of Health, Malaysia, 2021.</comment></element-citation></ref>
<ref id="b6-WASJ-7-3-00328"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>JJC</given-names></name><name><surname>Pilch</surname><given-names>BZ</given-names></name><name><surname>Kuo</surname><given-names>TT</given-names></name><name><surname>Wenig</surname><given-names>BM</given-names></name><name><surname>Lee</surname><given-names>AWM</given-names></name></person-group><comment>Tumours of the nasopharynx. In: World Health Organization Classification of Tumours: Pathology and Genetics of Head and Neck Tumours. Barnes L, Eveson JW, Reichart P and Sidransky D (eds.). IARC Press, Lyon, 2005.</comment></element-citation></ref>
<ref id="b7-WASJ-7-3-00328"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poh</surname><given-names>SS</given-names></name><name><surname>Chua</surname><given-names>MLK</given-names></name><name><surname>Wee</surname><given-names>JTS</given-names></name></person-group><article-title>Carcinogenesis of nasopharyngeal carcinoma: Aan alternate hypothetical mechanism</article-title><source>Chin J Cancer</source><volume>35</volume><issue>9</issue><year>2016</year><pub-id pub-id-type="pmid">26738743</pub-id><pub-id pub-id-type="doi">10.1186/s40880-015-0068-9</pub-id></element-citation></ref>
<ref id="b8-WASJ-7-3-00328"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chua</surname><given-names>MLK</given-names></name><name><surname>Wee</surname><given-names>JTS</given-names></name><name><surname>Hui</surname><given-names>EP</given-names></name><name><surname>Chan</surname><given-names>ATC</given-names></name></person-group><article-title>Nasopharyngeal carcinoma</article-title><source>Lancet</source><volume>387</volume><fpage>1012</fpage><lpage>1024</lpage><year>2016</year><pub-id pub-id-type="pmid">26321262</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(15)00055-0</pub-id></element-citation></ref>
<ref id="b9-WASJ-7-3-00328"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsao</surname><given-names>SW</given-names></name><name><surname>Yip</surname><given-names>YL</given-names></name><name><surname>Tsang</surname><given-names>CM</given-names></name><name><surname>Pang</surname><given-names>PS</given-names></name><name><surname>Lau</surname><given-names>VM</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Lo</surname><given-names>KW</given-names></name></person-group><article-title>Etiological factors of nasopharyngeal carcinoma</article-title><source>Oral Oncol</source><volume>50</volume><fpage>330</fpage><lpage>338</lpage><year>2014</year><pub-id pub-id-type="pmid">24630258</pub-id><pub-id pub-id-type="doi">10.1016/j.oraloncology.2014.02.006</pub-id></element-citation></ref>
<ref id="b10-WASJ-7-3-00328"><label>10</label><element-citation publication-type="journal"><comment>Epidemiology of Cancer in Sarawak 2007-2011. Sarawak Cancer Registry, Sarawak Health Department, Malaysia, 2017.</comment></element-citation></ref>
<ref id="b11-WASJ-7-3-00328"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linton</surname><given-names>RE</given-names></name><name><surname>Daker</surname><given-names>M</given-names></name><name><surname>Khoo</surname><given-names>ASB</given-names></name><name><surname>Choo</surname><given-names>DCY</given-names></name><name><surname>Viljoen</surname><given-names>M</given-names></name><name><surname>Neilsen</surname><given-names>PM</given-names></name></person-group><article-title>Nasopharyngeal carcinoma among the Bidayuh of Sarawak, Malaysia: History and risk factors</article-title><source>Oncol Lett</source><volume>22</volume><issue>514</issue><year>2021</year><pub-id pub-id-type="pmid">33986874</pub-id><pub-id pub-id-type="doi">10.3892/ol.2021.12775</pub-id></element-citation></ref>
<ref id="b12-WASJ-7-3-00328"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Gan</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Jin</surname><given-names>B</given-names></name></person-group><article-title>Plant flavonoids: Classification, distribution, biosynthesis, and antioxidant activity</article-title><source>Food Chem</source><volume>383</volume><issue>132531</issue><year>2022</year><pub-id pub-id-type="pmid">35413752</pub-id><pub-id pub-id-type="doi">10.1016/j.foodchem.2022.132531</pub-id></element-citation></ref>
<ref id="b13-WASJ-7-3-00328"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>XY</given-names></name><name><surname>Luo</surname><given-names>DH</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Mo</surname><given-names>HY</given-names></name><name><surname>Sun</surname><given-names>R</given-names></name><name><surname>Guo</surname><given-names>SS</given-names></name><name><surname>Liu</surname><given-names>LT</given-names></name><name><surname>Yang</surname><given-names>ZC</given-names></name><name><surname>Yang</surname><given-names>JH</given-names></name><name><surname>Qiu</surname><given-names>F</given-names></name><etal/></person-group><article-title>Deintensified chemoradiotherapy for pretreatment Epstein-barr virus DNA-selected low-risk locoregionally advanced nasopharyngeal carcinoma: A phase II randomized noninferiority trial</article-title><source>J Clin Oncol</source><volume>40</volume><fpage>1163</fpage><lpage>1173</lpage><year>2022</year><pub-id pub-id-type="pmid">34990291</pub-id><pub-id pub-id-type="doi">10.1200/JCO.21.01467</pub-id></element-citation></ref>
<ref id="b14-WASJ-7-3-00328"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>QN</given-names></name><name><surname>Liu</surname><given-names>LT</given-names></name><name><surname>Qi</surname><given-names>B</given-names></name><name><surname>Guo</surname><given-names>SS</given-names></name><name><surname>Luo</surname><given-names>DH</given-names></name><name><surname>Sun</surname><given-names>R</given-names></name><name><surname>Sun</surname><given-names>XS</given-names></name><name><surname>Chen</surname><given-names>DP</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Mo</surname><given-names>HY</given-names></name><etal/></person-group><article-title>Effect of concurrent chemoradiotherapy with nedaplatin vs cisplatin on the long-term outcomes of survival and toxic effects among patients with stage II to IVB nasopharyngeal carcinoma: A 5-year follow-up secondary analysis of a randomized clinical trial</article-title><source>JAMA Netw Open</source><volume>4</volume><issue>e2138470</issue><year>2021</year><pub-id pub-id-type="pmid">34928359</pub-id><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2021.38470</pub-id></element-citation></ref>
<ref id="b15-WASJ-7-3-00328"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuhlmann</surname><given-names>MK</given-names></name><name><surname>Horsch</surname><given-names>E</given-names></name><name><surname>Burkhardt</surname><given-names>G</given-names></name><name><surname>Wagner</surname><given-names>M</given-names></name><name><surname>Köhler</surname><given-names>H</given-names></name></person-group><article-title>Reduction of cisplatin toxicity in cultured renal tubular cells by the bioflavonoid quercetin</article-title><source>Arch Toxicol</source><volume>72</volume><fpage>536</fpage><lpage>540</lpage><year>1998</year><pub-id pub-id-type="pmid">9765070</pub-id><pub-id pub-id-type="doi">10.1007/s002040050539</pub-id></element-citation></ref>
<ref id="b16-WASJ-7-3-00328"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez-Gonzalez</surname><given-names>PD</given-names></name><name><surname>Lopez-Hernandez</surname><given-names>FJ</given-names></name><name><surname>Perez-Barriocanal</surname><given-names>F</given-names></name><name><surname>Morales</surname><given-names>AI</given-names></name><name><surname>Lopez-Novoa</surname><given-names>JM</given-names></name></person-group><article-title>Quercetin reduces cisplatin nephrotoxicity in rats without compromising its anti-tumour activity</article-title><source>Nephrol Dial Transplant</source><volume>26</volume><fpage>3484</fpage><lpage>3495</lpage><year>2011</year><pub-id pub-id-type="pmid">21602180</pub-id><pub-id pub-id-type="doi">10.1093/ndt/gfr195</pub-id></element-citation></ref>
<ref id="b17-WASJ-7-3-00328"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nho</surname><given-names>JH</given-names></name><name><surname>Jung</surname><given-names>HK</given-names></name><name><surname>Lee</surname><given-names>MJ</given-names></name><name><surname>Jang</surname><given-names>JH</given-names></name><name><surname>Sim</surname><given-names>MO</given-names></name><name><surname>Jeong</surname><given-names>DE</given-names></name><name><surname>Cho</surname><given-names>HW</given-names></name><name><surname>Kim</surname><given-names>JC</given-names></name></person-group><article-title>Beneficial effects of cynaroside on cisplatin-induced kidney injury in vitro and in vivo</article-title><source>Toxicol Res</source><volume>34</volume><fpage>133</fpage><lpage>141</lpage><year>2018</year><pub-id pub-id-type="pmid">29686775</pub-id><pub-id pub-id-type="doi">10.5487/TR.2018.34.2.133</pub-id></element-citation></ref>
<ref id="b18-WASJ-7-3-00328"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amado</surname><given-names>NG</given-names></name><name><surname>Cerqueira</surname><given-names>DM</given-names></name><name><surname>Menezes</surname><given-names>FS</given-names></name><name><surname>Mendes da Silva</surname><given-names>JF</given-names></name><name><surname>Neto</surname><given-names>VM</given-names></name><name><surname>Abreu</surname><given-names>JG</given-names></name></person-group><article-title>Isoquercitrin isolated from Hyptis fasciculata reduces glioblastoma cell proliferation and changes beta-catenin cellular localization</article-title><source>Anticancer Drugs</source><volume>20</volume><fpage>543</fpage><lpage>552</lpage><year>2009</year><pub-id pub-id-type="pmid">19491660</pub-id><pub-id pub-id-type="doi">10.1097/CAD.0b013e32832d1149</pub-id></element-citation></ref>
<ref id="b19-WASJ-7-3-00328"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daker</surname><given-names>M</given-names></name><name><surname>Ahmad</surname><given-names>M</given-names></name><name><surname>Khoo</surname><given-names>ASB</given-names></name></person-group><article-title>Quercetin-induced inhibition and synergistic activity with cisplatin-a chemotherapeutic strategy for nasopharyngeal carcinoma cells</article-title><source>Cancer Cell Int</source><volume>12</volume><issue>34</issue><year>2012</year><pub-id pub-id-type="pmid">22809533</pub-id><pub-id pub-id-type="doi">10.1186/1475-2867-12-34</pub-id></element-citation></ref>
<ref id="b20-WASJ-7-3-00328"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeong</surname><given-names>JC</given-names></name><name><surname>Kim</surname><given-names>MS</given-names></name><name><surname>Kim</surname><given-names>TH</given-names></name><name><surname>Kim</surname><given-names>YK</given-names></name></person-group><article-title>Kaempferol induces cell death through ERK and Akt-dependent down-regulation of XIAP and survivin in human glioma cells</article-title><source>Neurochem Res</source><volume>34</volume><fpage>991</fpage><lpage>1001</lpage><year>2009</year><pub-id pub-id-type="pmid">18949556</pub-id><pub-id pub-id-type="doi">10.1007/s11064-008-9868-5</pub-id></element-citation></ref>
<ref id="b21-WASJ-7-3-00328"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lefort</surname><given-names>ÉC</given-names></name><name><surname>Blay</surname><given-names>J</given-names></name></person-group><article-title>Apigenin and its impact on gastrointestinal cancers</article-title><source>Mol Nutr Food Res</source><volume>57</volume><fpage>126</fpage><lpage>144</lpage><year>2013</year><pub-id pub-id-type="pmid">23197449</pub-id><pub-id pub-id-type="doi">10.1002/mnfr.201200424</pub-id></element-citation></ref>
<ref id="b22-WASJ-7-3-00328"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name></person-group><article-title>Quercetin acts as a novel anti-cancer drug to suppress cancer aggressiveness and cisplatin-resistance in nasopharyngeal carcinoma (NPC) through regulating the yes-associated protein/Hippo signaling pathway</article-title><source>Immunobiology</source><volume>228</volume><issue>152324</issue><year>2023</year><pub-id pub-id-type="pmid">36608594</pub-id><pub-id pub-id-type="doi">10.1016/j.imbio.2022.152324</pub-id></element-citation></ref>
<ref id="b23-WASJ-7-3-00328"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>DY</given-names></name><name><surname>Jeong</surname><given-names>Y</given-names></name><name><surname>Tyner</surname><given-names>AL</given-names></name><name><surname>Park</surname><given-names>JHY</given-names></name></person-group><article-title>Induction of cell cycle arrest and apoptosis in HT-29 human colon cancer cells by the dietary compound luteolin</article-title><source>Am J Physiol Gastrointest Liver Physiol</source><volume>292</volume><fpage>G66</fpage><lpage>G75</lpage><year>2007</year><pub-id pub-id-type="pmid">16901994</pub-id><pub-id pub-id-type="doi">10.1152/ajpgi.00248.2006</pub-id></element-citation></ref>
<ref id="b24-WASJ-7-3-00328"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pacifico</surname><given-names>S</given-names></name><name><surname>Scognamiglio</surname><given-names>M</given-names></name><name><surname>D'Abrosca</surname><given-names>B</given-names></name><name><surname>Piccolella</surname><given-names>S</given-names></name><name><surname>Tsafantakis</surname><given-names>N</given-names></name><name><surname>Gallicchio</surname><given-names>M</given-names></name><name><surname>Ricci</surname><given-names>A</given-names></name><name><surname>Fiorentino</surname><given-names>A</given-names></name></person-group><article-title>Spectroscopic characterization and antiproliferative activity on HepG2 human hepatoblastoma cells of flavonoid C-glycosides from petrorhagia velutina</article-title><source>J Nat Prod</source><volume>73</volume><fpage>1973</fpage><lpage>1978</lpage><year>2010</year><pub-id pub-id-type="pmid">21080643</pub-id><pub-id pub-id-type="doi">10.1021/np100255u</pub-id></element-citation></ref>
<ref id="b25-WASJ-7-3-00328"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>González-Molina</surname><given-names>E</given-names></name><name><surname>Domínguez-Perles</surname><given-names>R</given-names></name><name><surname>Moreno</surname><given-names>DA</given-names></name><name><surname>García-Viguera</surname><given-names>C</given-names></name></person-group><article-title>Natural bioactive compounds of Citrus limon for food and health</article-title><source>J Pharm Biomed Anal</source><volume>51</volume><fpage>327</fpage><lpage>345</lpage><year>2010</year><pub-id pub-id-type="pmid">19748198</pub-id><pub-id pub-id-type="doi">10.1016/j.jpba.2009.07.027</pub-id></element-citation></ref>
<ref id="b26-WASJ-7-3-00328"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>JH</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>BY</given-names></name></person-group><article-title>Comparative evaluation of cytotoxicity and antioxidative activity of 20 flavonoids</article-title><source>J Agric Food Chem</source><volume>56</volume><fpage>3876</fpage><lpage>3883</lpage><year>2008</year><pub-id pub-id-type="pmid">18433100</pub-id><pub-id pub-id-type="doi">10.1021/jf073520n</pub-id></element-citation></ref>
<ref id="b27-WASJ-7-3-00328"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sak</surname><given-names>K</given-names></name></person-group><article-title>Cytotoxicity of dietary flavonoids on different human cancer types</article-title><source>Pharmacogn Rev</source><volume>8</volume><fpage>122</fpage><lpage>146</lpage><year>2014</year><pub-id pub-id-type="pmid">25125885</pub-id><pub-id pub-id-type="doi">10.4103/0973-7847.134247</pub-id></element-citation></ref>
<ref id="b28-WASJ-7-3-00328"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panche</surname><given-names>AN</given-names></name><name><surname>Diwan</surname><given-names>AD</given-names></name><name><surname>Chandra</surname><given-names>SR</given-names></name></person-group><article-title>Flavonoids: An overview</article-title><source>J Nutr Sci</source><volume>5</volume><issue>e47</issue><year>2016</year><pub-id pub-id-type="pmid">28620474</pub-id><pub-id pub-id-type="doi">10.1017/jns.2016.41</pub-id></element-citation></ref>
<ref id="b29-WASJ-7-3-00328"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahmud</surname><given-names>AR</given-names></name><name><surname>Ema</surname><given-names>TI</given-names></name><name><surname>Siddiquee</surname><given-names>MFR</given-names></name><name><surname>Shahriar</surname><given-names>A</given-names></name><name><surname>Ahmed</surname><given-names>H</given-names></name><name><surname>Mosfeq-Ul-Hasan</surname><given-names>M</given-names></name><name><surname>Rahman</surname><given-names>N</given-names></name><name><surname>Islam</surname><given-names>R</given-names></name><name><surname>Uddin</surname><given-names>MR</given-names></name><name><surname>Mizan</surname><given-names>MFR</given-names></name></person-group><article-title>Natural flavonols: Actions, mechanisms, and potential therapeutic utility for various diseases</article-title><source>Beni Suef Univ J Basic Appl Sci</source><volume>12</volume><issue>47</issue><year>2023</year><pub-id pub-id-type="pmid">37216013</pub-id><pub-id pub-id-type="doi">10.1186/s43088-023-00387-4</pub-id></element-citation></ref>
<ref id="b30-WASJ-7-3-00328"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Khayri</surname><given-names>JM</given-names></name><name><surname>Sahana</surname><given-names>GR</given-names></name><name><surname>Nagella</surname><given-names>P</given-names></name><name><surname>Joseph</surname><given-names>BV</given-names></name><name><surname>Alessa</surname><given-names>FM</given-names></name><name><surname>Al-Mssallem</surname><given-names>MQ</given-names></name></person-group><article-title>Flavonoids as potential anti-inflammatory molecules: A review</article-title><source>Molecules</source><volume>27</volume><issue>2901</issue><year>2022</year><pub-id pub-id-type="pmid">35566252</pub-id><pub-id pub-id-type="doi">10.3390/molecules27092901</pub-id></element-citation></ref>
<ref id="b31-WASJ-7-3-00328"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Cheng</surname><given-names>L</given-names></name><name><surname>Zhong</surname><given-names>C</given-names></name><name><surname>An</surname><given-names>J</given-names></name><name><surname>Zou</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name></person-group><article-title>Flavokawain C inhibits glucose metabolism and tumor angiogenesis in nasopharyngeal carcinoma by targeting the HSP90B1/STAT3/HK2 signaling axis</article-title><source>Cancer Cell Int</source><volume>24</volume><issue>158</issue><year>2024</year><pub-id pub-id-type="pmid">38711062</pub-id><pub-id pub-id-type="doi">10.1186/s12935-024-03314-4</pub-id></element-citation></ref>
<ref id="b32-WASJ-7-3-00328"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>CC</given-names></name><name><surname>Fang</surname><given-names>CY</given-names></name><name><surname>Cheng</surname><given-names>YJ</given-names></name><name><surname>Hsu</surname><given-names>HY</given-names></name><name><surname>Chou</surname><given-names>SP</given-names></name><name><surname>Huang</surname><given-names>SY</given-names></name><name><surname>Tsai</surname><given-names>CH</given-names></name><name><surname>Chen</surname><given-names>JY</given-names></name></person-group><article-title>Inhibition of epstein-barr virus reactivation by the flavonoid apigenin</article-title><source>J Biomed Sci</source><volume>24</volume><issue>2</issue><year>2017</year><pub-id pub-id-type="pmid">28056971</pub-id><pub-id pub-id-type="doi">10.1186/s12929-016-0313-9</pub-id></element-citation></ref>
<ref id="b33-WASJ-7-3-00328"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>CC</given-names></name><name><surname>Fang</surname><given-names>CY</given-names></name><name><surname>Hsu</surname><given-names>HY</given-names></name><name><surname>Chen</surname><given-names>YJ</given-names></name><name><surname>Chou</surname><given-names>SP</given-names></name><name><surname>Huang</surname><given-names>SY</given-names></name><name><surname>Cheng</surname><given-names>YJ</given-names></name><name><surname>Lin</surname><given-names>SF</given-names></name><name><surname>Chang</surname><given-names>Y</given-names></name><name><surname>Tsai</surname><given-names>CH</given-names></name><name><surname>Chen</surname><given-names>JY</given-names></name></person-group><article-title>Luteolin inhibits Epstein-Barr virus lytic reactivation by repressing the promoter activities of immediate-early genes</article-title><source>Antiviral Res</source><volume>132</volume><fpage>99</fpage><lpage>110</lpage><year>2016</year><pub-id pub-id-type="pmid">27185626</pub-id><pub-id pub-id-type="doi">10.1016/j.antiviral.2016.05.007</pub-id></element-citation></ref>
<ref id="b34-WASJ-7-3-00328"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>CC</given-names></name><name><surname>Fang</surname><given-names>CY</given-names></name><name><surname>Hsu</surname><given-names>HY</given-names></name><name><surname>Chuang</surname><given-names>HY</given-names></name><name><surname>Cheng</surname><given-names>YJ</given-names></name><name><surname>Chen</surname><given-names>YJ</given-names></name><name><surname>Chou</surname><given-names>SP</given-names></name><name><surname>Huang</surname><given-names>SY</given-names></name><name><surname>Lin</surname><given-names>SF</given-names></name><name><surname>Chang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>EBV reactivation as a target of luteolin to repress NPC tumorigenesis</article-title><source>Oncotarget</source><volume>7</volume><fpage>18999</fpage><lpage>19017</lpage><year>2016</year><pub-id pub-id-type="pmid">26967558</pub-id><pub-id pub-id-type="doi">10.18632/oncotarget.7967</pub-id></element-citation></ref>
<ref id="b35-WASJ-7-3-00328"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>CC</given-names></name><name><surname>Lee</surname><given-names>TY</given-names></name><name><surname>Cheng</surname><given-names>YJ</given-names></name><name><surname>Cho</surname><given-names>DY</given-names></name><name><surname>Chen</surname><given-names>JY</given-names></name></person-group><article-title>The dietary flavonol kaempferol inhibits Epstein-Barr virus reactivation in nasopharyngeal carcinoma cells</article-title><source>Molecules</source><volume>27</volume><issue>8158</issue><year>2022</year><pub-id pub-id-type="pmid">36500249</pub-id><pub-id pub-id-type="doi">10.3390/molecules27238158</pub-id></element-citation></ref>
<ref id="b36-WASJ-7-3-00328"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baloche</surname><given-names>V</given-names></name><name><surname>Ferrand</surname><given-names>F-R</given-names></name><name><surname>Makowska</surname><given-names>A</given-names></name><name><surname>Even</surname><given-names>C</given-names></name><name><surname>Kontny</surname><given-names>U</given-names></name><name><surname>Busson</surname><given-names>P</given-names></name></person-group><article-title>Emerging therapeutic targets for nasopharyngeal carcinoma: Opportunities and challenges</article-title><source>Expert Opin Ther Targets</source><volume>24</volume><fpage>545</fpage><lpage>558</lpage><year>2020</year><pub-id pub-id-type="pmid">32249657</pub-id><pub-id pub-id-type="doi">10.1080/14728222.2020.1751820</pub-id></element-citation></ref>
<ref id="b37-WASJ-7-3-00328"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>DP</given-names></name><name><surname>Ho</surname><given-names>JHC</given-names></name><name><surname>Poon</surname><given-names>YF</given-names></name><name><surname>Chew</surname><given-names>EC</given-names></name><name><surname>Saw</surname><given-names>D</given-names></name><name><surname>Lui</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>CL</given-names></name><name><surname>Mak</surname><given-names>LS</given-names></name><name><surname>Lai</surname><given-names>SH</given-names></name><name><surname>Lau</surname><given-names>WH</given-names></name></person-group><article-title>Establishment of a cell line (NPC/HK1) from a differentiated squamous carcinoma of the nasopharynx</article-title><source>Int J Cancer</source><volume>26</volume><fpage>127</fpage><lpage>132</lpage><year>1980</year><pub-id pub-id-type="pmid">6259064</pub-id><pub-id pub-id-type="doi">10.1002/ijc.2910260202</pub-id></element-citation></ref>
<ref id="b38-WASJ-7-3-00328"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheung</surname><given-names>ST</given-names></name><name><surname>Huang</surname><given-names>DP</given-names></name><name><surname>Hui</surname><given-names>ABY</given-names></name><name><surname>Lo</surname><given-names>KW</given-names></name><name><surname>Ko</surname><given-names>CW</given-names></name><name><surname>Tsang</surname><given-names>YS</given-names></name><name><surname>Wong</surname><given-names>N</given-names></name><name><surname>Whitney</surname><given-names>BM</given-names></name><name><surname>Lee</surname><given-names>JC</given-names></name></person-group><article-title>Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus</article-title><source>Int J Cancer</source><volume>83</volume><fpage>121</fpage><lpage>126</lpage><year>1999</year><pub-id pub-id-type="pmid">10449618</pub-id><pub-id pub-id-type="doi">10.1002/(sici)1097-0215(19990924)83:1&lt;121::aid-ijc21&gt;3.0.co;2-f</pub-id></element-citation></ref>
<ref id="b39-WASJ-7-3-00328"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boukamp</surname><given-names>P</given-names></name><name><surname>Petrussevska</surname><given-names>RT</given-names></name><name><surname>Breitkreutz</surname><given-names>D</given-names></name><name><surname>Hornung</surname><given-names>J</given-names></name><name><surname>Markham</surname><given-names>A</given-names></name><name><surname>Fusenig</surname><given-names>NE</given-names></name></person-group><article-title>Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line</article-title><source>J Cell Biol</source><volume>106</volume><fpage>761</fpage><lpage>771</lpage><year>1988</year><pub-id pub-id-type="pmid">2450098</pub-id><pub-id pub-id-type="doi">10.1083/jcb.106.3.761</pub-id></element-citation></ref>
<ref id="b40-WASJ-7-3-00328"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>HM</given-names></name><name><surname>Man</surname><given-names>C</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Deng</surname><given-names>W</given-names></name><name><surname>Yip</surname><given-names>YL</given-names></name><name><surname>Feng</surname><given-names>HC</given-names></name><name><surname>Cheung</surname><given-names>YC</given-names></name><name><surname>Lo</surname><given-names>KW</given-names></name><name><surname>Meltzer</surname><given-names>PS</given-names></name><name><surname>Wu</surname><given-names>ZG</given-names></name><etal/></person-group><article-title>Molecular and cytogenetic changes involved in the immortalization of nasopharyngeal epithelial cells by telomerase</article-title><source>Int J Cancer</source><volume>119</volume><fpage>1567</fpage><lpage>1576</lpage><year>2006</year><pub-id pub-id-type="pmid">16688717</pub-id><pub-id pub-id-type="doi">10.1002/ijc.22032</pub-id></element-citation></ref>
<ref id="b41-WASJ-7-3-00328"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsao</surname><given-names>SW</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Cheung</surname><given-names>YC</given-names></name><name><surname>Feng</surname><given-names>H</given-names></name><name><surname>Zheng</surname><given-names>Z</given-names></name><name><surname>Wong</surname><given-names>N</given-names></name><name><surname>Yuen</surname><given-names>PW</given-names></name><name><surname>Lo</surname><given-names>AK</given-names></name><name><surname>Wong</surname><given-names>YC</given-names></name><name><surname>Huang</surname><given-names>DP</given-names></name></person-group><article-title>Establishment of two immortalized nasopharyngeal epithelial cell lines using SV40 large T and HPV16E6/E7 viral oncogenes</article-title><source>Biochim Biophys Acta</source><volume>1590</volume><fpage>150</fpage><lpage>158</lpage><year>2002</year><pub-id pub-id-type="pmid">12063178</pub-id><pub-id pub-id-type="doi">10.1016/s0167-4889(02)00208-2</pub-id></element-citation></ref>
<ref id="b42-WASJ-7-3-00328"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daker</surname><given-names>M</given-names></name><name><surname>Jayaweera</surname><given-names>U</given-names></name><name><surname>Marzuki</surname><given-names>M</given-names></name><name><surname>Gunasegaran</surname><given-names>G</given-names></name><name><surname>Chew</surname><given-names>YL</given-names></name><name><surname>Ahmad</surname><given-names>M</given-names></name><name><surname>Akowuah</surname><given-names>GA</given-names></name></person-group><article-title>Content of luteolin and luteolin-7-О-glucoside from the leaves of Vernonia amygdalina Del., and synergistic inhibitory effect with cisplatin on nasopharyngeal carcinoma cells</article-title><source>Chem Data Collections</source><volume>45</volume><issue>101039</issue><year>2023</year></element-citation></ref>
<ref id="b43-WASJ-7-3-00328"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radha Abbas Hasoon</surname><given-names>M</given-names></name><name><surname>Jawad Kadhim</surname><given-names>N</given-names></name></person-group><article-title>Improvement of the selectivity index (SI) and cytotoxicity activity of doxorubicin drug by panax ginseng plant extract</article-title><source>Arch Razi Inst</source><volume>76</volume><fpage>659</fpage><lpage>666</lpage><year>2021</year><pub-id pub-id-type="pmid">34824758</pub-id><pub-id pub-id-type="doi">10.22092/ari.2021.355413.1681</pub-id></element-citation></ref>
<ref id="b44-WASJ-7-3-00328"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee Erinna</surname><given-names>F</given-names></name><name><surname>Dewson</surname><given-names>G</given-names></name><name><surname>Smith Brian</surname><given-names>J</given-names></name><name><surname>Evangelista</surname><given-names>M</given-names></name><name><surname>Pettikiriarachchi</surname><given-names>A</given-names></name><name><surname>Dogovski</surname><given-names>C</given-names></name><name><surname>Perugini</surname><given-names>MA</given-names></name><name><surname>Colman</surname><given-names>PM</given-names></name><name><surname>Fairlie</surname><given-names>WD</given-names></name></person-group><article-title>Crystal structure of a BCL-W Domain-swapped dimer: Implications for the function of BCL-2 family proteins</article-title><source>Structure</source><volume>19</volume><fpage>1467</fpage><lpage>1476</lpage><year>2011</year><pub-id pub-id-type="pmid">22000515</pub-id><pub-id pub-id-type="doi">10.1016/j.str.2011.07.015</pub-id></element-citation></ref>
<ref id="b45-WASJ-7-3-00328"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berman</surname><given-names>HM</given-names></name><name><surname>Westbrook</surname><given-names>J</given-names></name><name><surname>Feng</surname><given-names>Z</given-names></name><name><surname>Gilliland</surname><given-names>G</given-names></name><name><surname>Bhat</surname><given-names>TN</given-names></name><name><surname>Weissig</surname><given-names>H</given-names></name><name><surname>Shindyalov</surname><given-names>IN</given-names></name><name><surname>Bourne</surname><given-names>P</given-names></name></person-group><article-title>The protein data bank</article-title><source>Nucleic Acids Res</source><volume>28</volume><fpage>235</fpage><lpage>242</lpage><year>2000</year><pub-id pub-id-type="pmid">10592235</pub-id><pub-id pub-id-type="doi">10.1093/nar/28.1.235</pub-id></element-citation></ref>
<ref id="b46-WASJ-7-3-00328"><label>46</label><element-citation publication-type="journal"><comment>BIOVIA Dassault Systèmes, Discovery Studio Visualizer, Version 4.1. San Diego: Dassault Systèmes, 2022.</comment></element-citation></ref>
<ref id="b47-WASJ-7-3-00328"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>GM</given-names></name><name><surname>Huey</surname><given-names>R</given-names></name><name><surname>Lindstrom</surname><given-names>W</given-names></name><name><surname>Sanner</surname><given-names>MF</given-names></name><name><surname>Belew</surname><given-names>RK</given-names></name><name><surname>Goodsell</surname><given-names>DS</given-names></name><name><surname>Olson</surname><given-names>AJ</given-names></name></person-group><article-title>AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility</article-title><source>J Comput Chem</source><volume>30</volume><fpage>2785</fpage><lpage>2791</lpage><year>2009</year><pub-id pub-id-type="pmid">19399780</pub-id><pub-id pub-id-type="doi">10.1002/jcc.21256</pub-id></element-citation></ref>
<ref id="b48-WASJ-7-3-00328"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>J</given-names></name><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name></person-group><article-title>Design, synthesis, molecular docking, and tumor resistance reversal activity evaluation of matrine derivative with thiophene structure</article-title><source>Molecules</source><volume>26</volume><fpage>417</fpage><lpage>429</lpage><year>2021</year><pub-id pub-id-type="pmid">33466857</pub-id><pub-id pub-id-type="doi">10.3390/molecules26020417</pub-id></element-citation></ref>
<ref id="b49-WASJ-7-3-00328"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eberhardt</surname><given-names>J</given-names></name><name><surname>Santos-Martins</surname><given-names>D</given-names></name><name><surname>Tillack</surname><given-names>AF</given-names></name><name><surname>Forli</surname><given-names>S</given-names></name></person-group><article-title>AutoDock Vina 1.2.0: New docking methods, expanded force field, and python bindings</article-title><source>J Chem Inf Model</source><volume>61</volume><fpage>3891</fpage><lpage>3898</lpage><year>2021</year><pub-id pub-id-type="pmid">34278794</pub-id><pub-id pub-id-type="doi">10.1021/acs.jcim.1c00203</pub-id></element-citation></ref>
<ref id="b50-WASJ-7-3-00328"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trott</surname><given-names>O</given-names></name><name><surname>Olson</surname><given-names>AJ</given-names></name></person-group><article-title>AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</article-title><source>J Comput Chem</source><volume>31</volume><fpage>455</fpage><lpage>461</lpage><year>2010</year><pub-id pub-id-type="pmid">19499576</pub-id><pub-id pub-id-type="doi">10.1002/jcc.21334</pub-id></element-citation></ref>
<ref id="b51-WASJ-7-3-00328"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aliyatul Fikroh</surname><given-names>R</given-names></name></person-group><article-title>Synthesis of halogen substituted chalcone againts cervical cancer (HeLa) cell lines using green method</article-title><source>J Tropical Chemistry Res Education</source><volume>5</volume><fpage>36</fpage><lpage>43</lpage><year>2023</year></element-citation></ref>
<ref id="b52-WASJ-7-3-00328"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdul Rahman</surname><given-names>SF</given-names></name><name><surname>Azlan</surname><given-names>A</given-names></name><name><surname>Lo</surname><given-names>KW</given-names></name><name><surname>Azzam</surname><given-names>G</given-names></name><name><surname>Mohana-Kumaran</surname><given-names>N</given-names></name></person-group><article-title>Dual inhibition of anti-apoptotic proteins BCL-XL and MCL-1 enhances cytotoxicity of nasopharyngeal carcinoma cells</article-title><source>Discover Oncol</source><volume>13</volume><issue>9</issue><year>2022</year><pub-id pub-id-type="pmid">35201512</pub-id><pub-id pub-id-type="doi">10.1007/s12672-022-00470-9</pub-id></element-citation></ref>
<ref id="b53-WASJ-7-3-00328"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patil</surname><given-names>JR</given-names></name><name><surname>Chidambara Murthy</surname><given-names>KN</given-names></name><name><surname>Jayaprakasha</surname><given-names>GK</given-names></name><name><surname>Chetti</surname><given-names>MB</given-names></name><name><surname>Patil</surname><given-names>BS</given-names></name></person-group><article-title>Bioactive compounds from mexican lime (Citrus aurantifolia) Juice induce apoptosis in human pancreatic cells</article-title><source>J Agric Food Chem</source><volume>57</volume><fpage>10933</fpage><lpage>10942</lpage><year>2009</year><pub-id pub-id-type="pmid">19919125</pub-id><pub-id pub-id-type="doi">10.1021/jf901718u</pub-id></element-citation></ref>
<ref id="b54-WASJ-7-3-00328"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Shen</surname><given-names>W</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name></person-group><article-title>Anti-proliferative and chemosensitizing effects of luteolin on human gastric cancer AGS cell line</article-title><source>Mol Cellular Biochem</source><volume>313</volume><fpage>125</fpage><lpage>132</lpage><year>2008</year><pub-id pub-id-type="pmid">18398671</pub-id><pub-id pub-id-type="doi">10.1007/s11010-008-9749-x</pub-id></element-citation></ref>
<ref id="b55-WASJ-7-3-00328"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>H</given-names></name><name><surname>Jiang</surname><given-names>BH</given-names></name><name><surname>King</surname><given-names>SM</given-names></name><name><surname>Chen</surname><given-names>YC</given-names></name></person-group><article-title>Inhibition of cell growth and VEGF expression in ovarian cancer cells by flavonoids</article-title><source>Nutr Cancer</source><volume>60</volume><fpage>800</fpage><lpage>809</lpage><year>2008</year><pub-id pub-id-type="pmid">19005980</pub-id><pub-id pub-id-type="doi">10.1080/01635580802100851</pub-id></element-citation></ref>
<ref id="b56-WASJ-7-3-00328"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Daniel</surname><given-names>KG</given-names></name><name><surname>Chen</surname><given-names>MS</given-names></name><name><surname>Kuhn</surname><given-names>DJ</given-names></name><name><surname>Landis-Piwowar</surname><given-names>KR</given-names></name><name><surname>Dou</surname><given-names>QP</given-names></name></person-group><article-title>Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells</article-title><source>Biochem Pharmacol</source><volume>69</volume><fpage>1421</fpage><lpage>1432</lpage><year>2005</year><pub-id pub-id-type="pmid">15857606</pub-id><pub-id pub-id-type="doi">10.1016/j.bcp.2005.02.022</pub-id></element-citation></ref>
<ref id="b57-WASJ-7-3-00328"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>Y</given-names></name><name><surname>Krisanapun</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Nualsanit</surname><given-names>T</given-names></name><name><surname>Sams</surname><given-names>C</given-names></name><name><surname>Peungvicha</surname><given-names>P</given-names></name><name><surname>Baek</surname><given-names>SJ</given-names></name></person-group><article-title>Molecular targets of apigenin in colorectal cancer cells: Involvement of p21, NAG-1 and p53</article-title><source>Eur J Cancer</source><volume>46</volume><fpage>3365</fpage><lpage>3374</lpage><year>2010</year><pub-id pub-id-type="pmid">20709524</pub-id><pub-id pub-id-type="doi">10.1016/j.ejca.2010.07.007</pub-id></element-citation></ref>
<ref id="b58-WASJ-7-3-00328"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakazaki</surname><given-names>E</given-names></name><name><surname>Tsolmon</surname><given-names>S</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Isoda</surname><given-names>H</given-names></name></person-group><article-title>Proteomic study of granulocytic differentiation induced by apigenin 7-glucoside in human promyelocytic leukemia HL-60 cells</article-title><source>Eur J Nutr</source><volume>52</volume><fpage>25</fpage><lpage>35</lpage><year>2013</year><pub-id pub-id-type="pmid">22113421</pub-id><pub-id pub-id-type="doi">10.1007/s00394-011-0282-4</pub-id></element-citation></ref>
<ref id="b59-WASJ-7-3-00328"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>Y</given-names></name><name><surname>Zhong</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>B</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>F</given-names></name><name><surname>He</surname><given-names>L</given-names></name><name><surname>Tian</surname><given-names>D</given-names></name><name><surname>He</surname><given-names>Y</given-names></name></person-group><article-title>Luteolin isolated from polygonum cuspidatum is a potential compound against nasopharyngeal carcinoma</article-title><source>Biomed Res Int</source><volume>2022</volume><issue>9740066</issue><year>2022</year><pub-id pub-id-type="pmid">36588531</pub-id><pub-id pub-id-type="doi">10.1155/2022/9740066</pub-id></element-citation></ref>
<ref id="b60-WASJ-7-3-00328"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asnaashari</surname><given-names>S</given-names></name><name><surname>Amjad</surname><given-names>E</given-names></name><name><surname>Sokouti</surname><given-names>B</given-names></name></person-group><article-title>Synergistic effects of flavonoids and paclitaxel in cancer treatment: A systematic review</article-title><source>Cancer Cell Int</source><volume>23</volume><issue>211</issue><year>2023</year><pub-id pub-id-type="pmid">37743502</pub-id><pub-id pub-id-type="doi">10.1186/s12935-023-03052-z</pub-id></element-citation></ref>
<ref id="b61-WASJ-7-3-00328"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pyo</surname><given-names>Y</given-names></name><name><surname>Kwon</surname><given-names>KH</given-names></name><name><surname>Jung</surname><given-names>YJ</given-names></name></person-group><article-title>Anticancer potential of flavonoids: Their role in cancer prevention and health benefits</article-title><source>Foods</source><volume>13</volume><issue>2253</issue><year>2024</year><pub-id pub-id-type="pmid">39063337</pub-id><pub-id pub-id-type="doi">10.3390/foods13142253</pub-id></element-citation></ref>
<ref id="b62-WASJ-7-3-00328"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menendez</surname><given-names>JA</given-names></name><name><surname>Lupu</surname><given-names>R</given-names></name></person-group><article-title>Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis</article-title><source>Nat Rev Cancer</source><volume>7</volume><fpage>763</fpage><lpage>777</lpage><year>2007</year><pub-id pub-id-type="pmid">17882277</pub-id><pub-id pub-id-type="doi">10.1038/nrc2222</pub-id></element-citation></ref>
<ref id="b63-WASJ-7-3-00328"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Qu</surname><given-names>Q</given-names></name></person-group><article-title>Mechanism of luteolin induces ferroptosis in nasopharyngeal carcinoma cells</article-title><source>J Toxicol Sci</source><volume>49</volume><fpage>399</fpage><lpage>408</lpage><year>2024</year><pub-id pub-id-type="pmid">39231684</pub-id><pub-id pub-id-type="doi">10.2131/jts.49.399</pub-id></element-citation></ref>
<ref id="b64-WASJ-7-3-00328"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Ji</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Shi</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Cui</surname><given-names>H</given-names></name></person-group><article-title>Morusin shows potent antitumor activity for melanoma through apoptosis induction and proliferation inhibition</article-title><source>BMC Cancer</source><volume>23</volume><issue>602</issue><year>2023</year><pub-id pub-id-type="pmid">37386395</pub-id><pub-id pub-id-type="doi">10.1186/s12885-023-11080-1</pub-id></element-citation></ref>
<ref id="b65-WASJ-7-3-00328"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abusaliya</surname><given-names>A</given-names></name><name><surname>Ha</surname><given-names>SE</given-names></name><name><surname>Bhosale</surname><given-names>PB</given-names></name><name><surname>Kim</surname><given-names>HH</given-names></name><name><surname>Park</surname><given-names>MY</given-names></name><name><surname>Vetrivel</surname><given-names>P</given-names></name><name><surname>Kim</surname><given-names>GS</given-names></name></person-group><article-title>Glycosidic flavonoids and their potential applications in cancer research: A review</article-title><source>Mol Cell Toxicol</source><volume>18</volume><fpage>9</fpage><lpage>16</lpage><year>2022</year></element-citation></ref>
<ref id="b66-WASJ-7-3-00328"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kale</surname><given-names>J</given-names></name><name><surname>Osterlund</surname><given-names>EJ</given-names></name><name><surname>Andrews</surname><given-names>DW</given-names></name></person-group><article-title>BCL-2 family proteins: Changing partners in the dance towards death</article-title><source>Cell Death Differ</source><volume>25</volume><fpage>65</fpage><lpage>80</lpage><year>2018</year><pub-id pub-id-type="pmid">29149100</pub-id><pub-id pub-id-type="doi">10.1038/cdd.2017.186</pub-id></element-citation></ref>
<ref id="b67-WASJ-7-3-00328"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartman</surname><given-names>ML</given-names></name><name><surname>Czyz</surname><given-names>M</given-names></name></person-group><article-title>BCL-w: Apoptotic and non-apoptotic role in health and disease</article-title><source>Cell Death Dis</source><volume>11</volume><issue>260</issue><year>2020</year><pub-id pub-id-type="pmid">32317622</pub-id><pub-id pub-id-type="doi">10.1038/s41419-020-2417-0</pub-id></element-citation></ref>
<ref id="b68-WASJ-7-3-00328"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugantha Priya</surname><given-names>E</given-names></name><name><surname>Selvakumar</surname><given-names>K</given-names></name><name><surname>Bavithra</surname><given-names>S</given-names></name><name><surname>Elumalai</surname><given-names>P</given-names></name><name><surname>Arunkumar</surname><given-names>R</given-names></name><name><surname>Raja Singh</surname><given-names>P</given-names></name><name><surname>Brindha Mercy</surname><given-names>A</given-names></name><name><surname>Arunakaran</surname><given-names>J</given-names></name></person-group><article-title>Anti-cancer activity of quercetin in neuroblastoma: An in vitro approach</article-title><source>Neurol Sci</source><volume>35</volume><fpage>163</fpage><lpage>170</lpage><year>2014</year><pub-id pub-id-type="pmid">23771516</pub-id><pub-id pub-id-type="doi">10.1007/s10072-013-1462-1</pub-id></element-citation></ref>
<ref id="b69-WASJ-7-3-00328"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taghizadeh</surname><given-names>MS</given-names></name><name><surname>Niazi</surname><given-names>A</given-names></name><name><surname>Moghadam</surname><given-names>A</given-names></name><name><surname>Afsharifar</surname><given-names>A</given-names></name></person-group><article-title>Experimental, molecular docking and molecular dynamic studies of natural products targeting overexpressed receptors in breast cancer</article-title><source>PLoS One</source><volume>17</volume><issue>e0267961</issue><year>2022</year><pub-id pub-id-type="pmid">35536789</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0267961</pub-id></element-citation></ref>
<ref id="b70-WASJ-7-3-00328"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Mei</surname><given-names>H</given-names></name></person-group><article-title>Binding site analysis, 3D-QSAR studies, and molecular design of flavonoids derivatives as potent neuraminidase inhibitors</article-title><source>Med Chemistry Res</source><volume>22</volume><fpage>606</fpage><lpage>614</lpage><year>2013</year></element-citation></ref>
<ref id="b71-WASJ-7-3-00328"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghanbari-Movahed</surname><given-names>M</given-names></name><name><surname>Shafiee</surname><given-names>S</given-names></name><name><surname>Burcher</surname><given-names>JT</given-names></name><name><surname>Lagoa</surname><given-names>R</given-names></name><name><surname>Farzaei</surname><given-names>MH</given-names></name><name><surname>Bishayee</surname><given-names>A</given-names></name></person-group><article-title>Anticancer potential of apigenin and isovitexin with focus on oncogenic metabolism in cancer stem cells</article-title><source>Metabolites</source><volume>13</volume><issue>404</issue><year>2023</year><pub-id pub-id-type="pmid">36984844</pub-id><pub-id pub-id-type="doi">10.3390/metabo13030404</pub-id></element-citation></ref>
<ref id="b72-WASJ-7-3-00328"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhagavatula</surname><given-names>D</given-names></name><name><surname>Hasan</surname><given-names>TN</given-names></name><name><surname>Vohra</surname><given-names>H</given-names></name><name><surname>Khorami</surname><given-names>S</given-names></name><name><surname>Hussain</surname><given-names>A</given-names></name></person-group><article-title>Delineating the antiapoptotic property of apigenin as an antitumor agent: A computational and in vitro study on HeLa cells</article-title><source>ACS Omega</source><volume>9</volume><fpage>24751</fpage><lpage>24760</lpage><year>2024</year><pub-id pub-id-type="pmid">38882173</pub-id><pub-id pub-id-type="doi">10.1021/acsomega.4c01300</pub-id></element-citation></ref>
<ref id="b73-WASJ-7-3-00328"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Cai</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>E</given-names></name><name><surname>Cui</surname><given-names>H</given-names></name></person-group><article-title>Effects of Cynaroside on cell proliferation, apoptosis, migration and invasion though the MET/AKT/mTOR axis in gastric cancer</article-title><source>Int J Mol Sci</source><volume>22</volume><issue>12125</issue><year>2021</year><pub-id pub-id-type="pmid">34830011</pub-id><pub-id pub-id-type="doi">10.3390/ijms222212125</pub-id></element-citation></ref>
<ref id="b74-WASJ-7-3-00328"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carrillo-Martinez</surname><given-names>EJ</given-names></name><name><surname>Flores-Hernández</surname><given-names>FY</given-names></name><name><surname>Salazar-Montes</surname><given-names>AM</given-names></name><name><surname>Nario-Chaidez</surname><given-names>HF</given-names></name><name><surname>Hernández-Ortega</surname><given-names>LD</given-names></name></person-group><article-title>Quercetin, a flavonoid with great pharmacological capacity</article-title><source>Molecules</source><volume>29</volume><issue>1000</issue><year>2024</year><pub-id pub-id-type="pmid">38474512</pub-id><pub-id pub-id-type="doi">10.3390/molecules29051000</pub-id></element-citation></ref>
</ref-list>
</back>
<floats-group>
<fig id="f1-WASJ-7-3-00328" position="float">
<label>Figure 1</label>
<caption><p>General structure of flavonoids.</p></caption>
<graphic xlink:href="wasj-07-03-00328-g00.tif"/>
</fig>
<fig id="f2-WASJ-7-3-00328" position="float">
<label>Figure 2</label>
<caption><p>Chemical structures of selected flavones and flavonols.</p></caption>
<graphic xlink:href="wasj-07-03-00328-g01.tif"/>
</fig>
<fig id="f3-WASJ-7-3-00328" position="float">
<label>Figure 3</label>
<caption><p>IC<sub>50</sub> values of (A) kaempferol and astragalin (kaempferol-3<italic>-O-</italic>glucoside), (B) apigenin and apigetrin (apigenin-7<italic>-O-</italic>glucoside), (C) luteolin and cynaroside (luteolin-7<italic>-O-</italic>glucoside), (D) quercetin and isoquercitrin (quercetin-3<italic>-O-</italic>glucoside), and (E) cisplatin, 1-3 days post-treatment on C666-1 and HK1 (NPC cells), NP460hTERT and NP69SV40T (immortalised nasopharyngeal epithelial cells), and HaCaT (immortalised human skin keratinocyte). Absent bars denote unattainable IC<sub>50</sub> values at the highest concentration tested.</p></caption>
<graphic xlink:href="wasj-07-03-00328-g02.tif"/>
</fig>
<fig id="f4-WASJ-7-3-00328" position="float">
<label>Figure 4</label>
<caption><p>Growth kinetics represented by time (x-axis) and normalised cell index (y-axis) generated by xCELLigence system depicting the effect of (A) kaempferol and astragalin (kaempferol-3<italic>-O-</italic>glucoside), (B) apigenin and apigetrin (apigenin-7<italic>-O-</italic>glucoside), on C666-1 and HK1 (NPC cells), NP460hTERT and NP69SV40T (immortalised nasopharyngeal epithelial cells), and (C) luteolin and cynaroside (luteolin-7<italic>-O-</italic>glucoside) on HaCaT (immortalised human skin keratinocyte).</p></caption>
<graphic xlink:href="wasj-07-03-00328-g03.tif"/>
</fig>
<fig id="f5-WASJ-7-3-00328" position="float">
<label>Figure 5</label>
<caption><p>Docking pose of cynaroside in the ligand binding site of BCL-w (PDB ID: 2Y6W).</p></caption>
<graphic xlink:href="wasj-07-03-00328-g04.tif"/>
</fig>
<fig id="f6-WASJ-7-3-00328" position="float">
<label>Figure 6</label>
<caption><p>Docking pose of apigetrin in the ligand binding site of BCL-w (PDB ID: 2Y6W).</p></caption>
<graphic xlink:href="wasj-07-03-00328-g05.tif"/>
</fig>
<fig id="f7-WASJ-7-3-00328" position="float">
<label>Figure 7</label>
<caption><p>Docking pose of isoorientin in the ligand binding site of BCL-w (PDB ID: 2Y6W).</p></caption>
<graphic xlink:href="wasj-07-03-00328-g06.tif"/>
</fig>
<fig id="f8-WASJ-7-3-00328" position="float">
<label>Figure 8</label>
<caption><p>Docking pose of isovitexin in the ligand binding site of BCL-w (PDB ID: 2Y6W).</p></caption>
<graphic xlink:href="wasj-07-03-00328-g07.tif"/>
</fig>
<table-wrap id="tI-WASJ-7-3-00328" position="float">
<label>Table I</label>
<caption><p>Selectivity index of immortalised nasopharyngeal epithelial cells and immortalised human skin keratinocyte against nasopharyngeal carcinoma cells at 1-3 days post-treatment.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="middle"> </th>
<th align="center" valign="middle" colspan="9">Epithelial, undifferentiated carcinoma C666-1</th>
<th align="center" valign="middle" colspan="9">Epithelial, squamous cell carcinoma HK1</th>
</tr>
<tr>
<th align="left" valign="middle"> </th>
<th align="center" valign="middle" colspan="3">Selectivity index, IC<sub>50</sub> NP460hTERT/IC<sub>50</sub> C666-1</th>
<th align="center" valign="middle" colspan="3">Selectivity index, IC<sub>50</sub> NP69SV40T/IC<sub>50</sub> C666-1</th>
<th align="center" valign="middle" colspan="3">Selectivity index, IC<sub>50</sub> HaCaT/IC<sub>50</sub> C666-1</th>
<th align="center" valign="middle" colspan="3">Selectivity index, IC<sub>50</sub> NP460hTERT/IC<sub>50</sub> HK1</th>
<th align="center" valign="middle" colspan="3">Selectivity index, IC<sub>50</sub> NP69SV40T/IC<sub>50</sub> HK1</th>
<th align="center" valign="middle" colspan="3">Selectivity index, IC<sub>50</sub> HaCaT/IC<sub>50</sub> HK1</th>
</tr>
<tr>
<th align="left" valign="middle">Standard chemotherapeutic drug or flavonoid</th>
<th align="center" valign="middle">Day 1</th>
<th align="center" valign="middle">Day 2</th>
<th align="center" valign="middle">Day 3</th>
<th align="center" valign="middle">Day 1</th>
<th align="center" valign="middle">Day 2</th>
<th align="center" valign="middle">Day 3</th>
<th align="center" valign="middle">Day 1</th>
<th align="center" valign="middle">Day 2</th>
<th align="center" valign="middle">Day 3</th>
<th align="center" valign="middle">Day 1</th>
<th align="center" valign="middle">Day 2</th>
<th align="center" valign="middle">Day 3</th>
<th align="center" valign="middle">Day 1</th>
<th align="center" valign="middle">Day 2</th>
<th align="center" valign="middle">Day 3</th>
<th align="center" valign="middle">Day 1</th>
<th align="center" valign="middle">Day 2</th>
<th align="center" valign="middle">Day 3</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">Cisplatin Flavonoid</td>
<td align="center" valign="middle">0.098</td>
<td align="center" valign="middle">0.137</td>
<td align="center" valign="middle">0.160</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">2.621</td>
<td align="center" valign="middle">0.880</td>
<td align="center" valign="middle">0.184</td>
<td align="center" valign="middle">0.158</td>
<td align="center" valign="middle">0.107</td>
<td align="center" valign="middle">0.172</td>
<td align="center" valign="middle">0.302</td>
<td align="center" valign="middle">0.462</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">5.791</td>
<td align="center" valign="middle">2.538</td>
<td align="center" valign="middle">0.324</td>
<td align="center" valign="middle">0.349</td>
<td align="center" valign="middle">0.308</td>
</tr>
<tr>
<td align="left" valign="middle">Apigenin</td>
<td align="center" valign="middle">2.302</td>
<td align="center" valign="middle">0.667</td>
<td align="center" valign="middle">0.240</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">2.039</td>
<td align="center" valign="middle">0.667</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">0.823</td>
<td align="center" valign="middle">0.444</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">0.654</td>
<td align="center" valign="middle">0.191</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">2</td>
<td align="center" valign="middle">0.529</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">0.808</td>
<td align="center" valign="middle">0.353</td>
</tr>
<tr>
<td align="left" valign="middle">Apigetrin (Apigenin-7-<italic>O</italic>-glucoside)</td>
<td align="center" valign="middle">0.696</td>
<td align="center" valign="middle">1.527</td>
<td align="center" valign="middle">2.976</td>
<td align="center" valign="middle">1.037</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">3.073</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">0.913</td>
<td align="center" valign="middle">2.825</td>
<td align="center" valign="middle">2.490</td>
<td align="center" valign="middle">1.359</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">2.571</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
</tr>
<tr>
<td align="left" valign="middle">Kaempferol</td>
<td align="center" valign="middle">0.797</td>
<td align="center" valign="middle">1.178</td>
<td align="center" valign="middle">0.869</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">0.733</td>
<td align="center" valign="middle">0.262</td>
<td align="center" valign="middle">0.699</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">2.836</td>
<td align="center" valign="middle">0.358</td>
<td align="center" valign="middle">0.752</td>
<td align="center" valign="middle">0.315</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">0.468</td>
<td align="center" valign="middle">0.095</td>
<td align="center" valign="middle">0.314</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">1.030</td>
</tr>
<tr>
<td align="left" valign="middle">Astragalin (Kaempferol-3-<italic>O</italic>-glucoside)</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
</tr>
<tr>
<td align="left" valign="middle">Luteolin</td>
<td align="center" valign="middle">0.440</td>
<td align="center" valign="middle">0.257</td>
<td align="center" valign="middle">0.282</td>
<td align="center" valign="middle">1.093</td>
<td align="center" valign="middle">0.314</td>
<td align="center" valign="middle">0.282</td>
<td align="center" valign="middle">1.520</td>
<td align="center" valign="middle">1.314</td>
<td align="center" valign="middle">1.821</td>
<td align="center" valign="middle">0.214</td>
<td align="center" valign="middle">0.173</td>
<td align="center" valign="middle">0.164</td>
<td align="center" valign="middle">0.532</td>
<td align="center" valign="middle">0.212</td>
<td align="center" valign="middle">0.164</td>
<td align="center" valign="middle">0.740</td>
<td align="center" valign="middle">0.885</td>
<td align="center" valign="middle">1.060</td>
</tr>
<tr>
<td align="left" valign="middle">Cynaroside (Luteolin-7-<italic>O</italic>-glucoside)</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
</tr>
<tr>
<td align="left" valign="middle">Quercetin</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">0.262</td>
<td align="center" valign="middle">0.421</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">0.152</td>
<td align="center" valign="middle">0.316</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">1.836</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">0.303</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">0.227</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">1.322</td>
</tr>
<tr>
<td align="left" valign="middle">Isoquercitrin (Quercetin-3-<italic>O</italic>-glucoside)</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">0.299</td>
<td align="center" valign="middle">0.008</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">0.025</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">NA</td>
<td align="center" valign="middle">0.644</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn><p>NA, IC<sub>50</sub> of normal cells not within reach at the highest concentration tested; -, IC<sub>50</sub> of cancer cells not within reach at the highest concentration tested.</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="tII-WASJ-7-3-00328" position="float">
<label>Table II</label>
<caption><p>Docking scores of the selected flavones, flavonols and their glycosidic derivatives.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="middle">Ligand</th>
<th align="center" valign="middle">Binding affinity (Kcal/mol)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">Apigenin</td>
<td align="center" valign="middle">-6.9</td>
</tr>
<tr>
<td align="left" valign="middle">Apigetrin</td>
<td align="center" valign="middle">-8.8</td>
</tr>
<tr>
<td align="left" valign="middle">Astragalin</td>
<td align="center" valign="middle">-7.9</td>
</tr>
<tr>
<td align="left" valign="middle">Cynaroside</td>
<td align="center" valign="middle">-9.1</td>
</tr>
<tr>
<td align="left" valign="middle">Isoorientin</td>
<td align="center" valign="middle">-8.2</td>
</tr>
<tr>
<td align="left" valign="middle">Isoquercitrin</td>
<td align="center" valign="middle">-7.9</td>
</tr>
<tr>
<td align="left" valign="middle">Isovitexin</td>
<td align="center" valign="middle">-8.2</td>
</tr>
<tr>
<td align="left" valign="middle">Kempferol</td>
<td align="center" valign="middle">-6.9</td>
</tr>
<tr>
<td align="left" valign="middle">Luteolin</td>
<td align="center" valign="middle">-7.7</td>
</tr>
<tr>
<td align="left" valign="middle">Orientin</td>
<td align="center" valign="middle">-7.9</td>
</tr>
<tr>
<td align="left" valign="middle">Quercetin</td>
<td align="center" valign="middle">-7.1</td>
</tr>
<tr>
<td align="left" valign="middle">Vitexin</td>
<td align="center" valign="middle">-7.6</td>
</tr>
</tbody>
</table>
</table-wrap>
</floats-group>
</article>
